annual report p e n n n v n p r n e r introduce ocrevus medicine people autism collaboration partner treatment form multiple spectrum disorder phase iii authority develop sclerosis ocrevus demonstrate study common nextgeneration diagnostic test superior efficacy reduce neurodevelopmental condition medicine aim relapse slow worsen characterise difficulty diagnose treat multi disability cause ms social interaction drugresistant bacterial infection content overview strategy chairman shareholder letter ceo shareholder letter business performance group performance diagnostic performance pharmaceutical performance science innovation identify medical need develop diagnostic test health app access healthcare join force difference enable sustainable healthcare fund people learn leadership development worldclass talent shape future environment reduce energy water consumption reduce emission air water community engagement strengthen local community partner difference integrity business ensure business continuity develop last partnership corporate governance board director corporate executive committee remuneration report principle remuneration component w ho innovation dna work discipline geography drive scientific discovery redefine possible improve patient live work understanding disease world leader vitro diagnostic differ molecular level business track record allow build last develop new test medicine prevent meaningful partnership world diagnose treat disease bring research academia public healthcare institution patient need combined strength diagnostic pharmaceutical found family continue hold majority personalise healthcare strategy aim fit voting stake company stability allow right treatment right patient tradition sustainable thinking learn setback focus last value patient world large biotech company develop society remain dedicated high breakthrough medicine improve standard standard quality safety integrity legacy care oncology immunology infectious base respect individual disease ophthalmology neuroscience community world live inroche global presence employee worldwide europe employees north america basel kaiseraugst rotkreuz switzerland employee mannheim penzberg germany genentech south san francisco roche diagnostic indianapoli asia employees chugai tokyo japan shanghai suzhou china latin america employees africa australianew zealand employee employee research development site pharmaceutical manufacturing site pharmaceutical diagnostic worldwide diagnostic worldwide roche group headquarters manufacturing site pharmaceutical diagnostic large site base number employee sale site pharmaceutical diagnostic research development site pharmaceutical diagnostic number employee express fulltime equivalentshighlight manage multiple sclerosis test infectious disease ocrevus successfully launch treatment form portfolio cobas liat system test extend fast multiple sclerosis debilitate disease diagnosis help control spread infectious disease read read treat rare blood disorder improve access healthcare hemlibra approve treatment people haemophilia reimbursement roche medicine china factor viii inhibitor blood disorder make available entire population read read progress cancer immunotherapy contribute sustainability result number tecentriq clinical study date roche rank sustainable healthcare company demonstrate significant medical benefit dow jones sustainability indices ninth year running read read key figure chf million chf million group sale r core investment chf million roche medicine core operate profit model list essential medicine chf million patient dividend treat roche medicine growth rate report constant exchange rate cer average por ting approach roche commit transparent reporting endeavour drive economic social environmental performance diligence financial performance report scope boundary business sustainability risk opportunity provide integrate information financial annual basis integrate exist online annual nonfinancial performance annual report risk management process report finance report online report arrochecom cover region division january consolidated group risk report cover december report scope define material risk discuss annually roche annual outlined finance report corporate executive committee review report pdf significant change scope compare audit committee board directors wwwrochecom board directors effectiveness arepdf reporting accordance late risk management process regularly monitor gri guideline group risk advisory team overall roche finance follow gri g guideline global process review externally appropriate risk report pdf reporting initiative gri management embed level group wwwrochecom guideline disclose critical impact pharmaceutical diagnostic division fbepdf activity environment society economy global function conduct formal risk assessment report period transition process year develop risk risk management newly introduce gri standard base plan material risk rochecomrisk key concept disclosure gri g management guideline report accordance standard group risk advisory facilitate risk discussion core level requirement support business specialist area core level number indicator security compliance sustainability training session platform establish risk management help employee manage monitor mitigate risk management policy set roches approach risk appropriately identify managing report internal external risk opportunity identify read corporate governance report approach roche material topic external assurance tier fundamental driver ability deliver current annual report include independent core purpose long term assurance report nonfinancial reporting prepare pricewaterhousecoopers ag rd pipeline strategy personalise healthcare employee engagement talent retention independent assurance report growth strategy emerge develop market product portfolio strategy materiality patent policy accordance gri standard conduct leadership commitment materiality analysis corporate level gather input feedback internal external source conference tier major influence factor business conduct regular interview oneonone success short medium term discussion key stakeholder result regularly vet ongoing stakeholder pricing research key market stakeholder group disease awareness treatment education enable include topic stakeholder compliance group consider important business drug efficacy safety counterfeit healthcare sector patient organisation supply chain management physicians laboratory staff employee medium biosimilar safety investor payer regulator government sustainable healthcare material topic screen priority deem key roche tiersfirstly fundamental driver ability deliver core purpose tier additional material topic long term secondly additional annually review major influence factor business success executive remuneration materiality short medium term finally compensationbenefit rochecom material topic provide level priority organisational effectiveness materiality address material topic environmental responsibility community engagement key performance tier material topic reflect patient organisation support indicator business priority report content highlight datum transparency clinical trial rochecom begin chapter aspect occupational accident performance boundary accord gri build concrete action relate topic operational activity measure performance define indicator strategy approach su stainability sustainability mean alignment individual goal interest society preserve natural resource ultimately help meet goal act sustainably contribution un sdgs contribute positively development world rochecomunsdgssdgs roche commit sustainability year contribute number united nations sustainable development goal sdgs innovate patient million patient treat roche medicine support billion test conduct roche diagnostic product sdg roche medicine model list essential medicine trustworthy partner new partnership diagnostic support new partnership pharmaceutical sdgs approximately businesscritical supplier riskassesse protect environment decrease water consumption support decrease energy consumption sdgs improvement ecobalance deliver continue growth group sale support core operating profit sdgs sustainability leader pharmaceutical biotechnology life science industry index djsi provide great workplace employee engagement rate support woman key leadership position sdgs key leader diverse work experience world health organization growth rate report constant exchange rate cer average focus people fitting treatment patient make mark distinctiveness decisionmake excellence science accountable transparent delivery structure value stakeholder build innovation itour strategy roche strateg focus find new medicine diagnostic help patient live long well life evolve practice medicine guide purpose deep understand molecular biology seamless patient need company integration pharmaceutical diagnostic year history advance field medicine capability diversity approach maximise bring novel treatment diagnostic patient innovation longterm orientation patient remain core reason come work day delivery create value stakeholder partner choice bring significant medical benefit patient doctor payer offer great place work employee sustainable impact society create topquartile total focus fitting treatment patient provide shareholder return investor right therapy respond group people right time inhouse combination pharmaceutical diagnostic uniquely position deliver personalise healthcare develop internal capability build strategic end take people integrity courage partnership ready stage personalise passion difference patient people healthcare combine insight multiple datum proud roche embrace source sophisticated analytic drive diversity culture people group effective efficient research allow well inclusive encourage richness idea therapeutic decision patient access product approach bring critical strategy detail access plan embed business local level decisionmake principle process emphasise transparent dialogue clear accountability continue concentrate energy entirely encourage high degree empowerment prescription medicine vitro diagnostic diversify sector like generic structure build innovation autonomous biosimilar overthecounter medicine research development centre alliance medical device external partner foster diversity agility global geographical scale reach enable pursuit excellence science distinctiveness bring diagnostic medicine quickly people rest key element exceptionally broad need mark et e nv ironme nt digital technology transform healthcare trial simple patient investigate doctor ongoing digital revolution drive radical participate minimise inconvenience transformation healthcare bring solution time effort entail improve research development patient involvement care outcomes costefficiency demand digital development make possible medical care continue grow transformation decentralise clinical study clinic hospital urgently need economic sustainability patient home doctorpatient interaction global healthcare expenditure project reach place virtually telemedicineenabled usd trillion usd trillion contact support digital diagnostic tracking place pressure healthcare system tool facilitate physical examination distance patient increase access key development technologysuch internet clinical study significantly reduce travel thing machine learn robotic deep waiting time inconvenience dataare enable enormous progress healthcare technology apply sophisticated analytic pilot cuttingedge clinical study design personalise healthcare result treatment strategy feature continual evaluation array unprecedented precision reality datum feed refine study well identify potential drug combination overall proper application development activity allow develop bring right safe help find solution complex challenge medicine patient efficient manner face patientcentred outcomesbase care whilst make efficient use improve treatment outcome resource solution bring wideranging improvement diagnostic possibility target benefit complex individual treatment strategy therapie combination medicine offer wide improve chronic care management range treatment choice complexity require clinical decision support tool innovationfocuse company forefront drive development diagnostic deep datum helping personalised healthcare pharmaceutical digital revolution new level roche partner company major impact key area flatiron health foundation medicine inc fmi ge healthcare help well leverage datum transform clinical study advanced analytic improve development roche conduct clinical trial medicine decisionmake patient care patient involve want datum new bloodbase assay measuringmarket environment roche expert develop industryleade platform use cuttingedge imaging science look inside tumour document effect new drug candidate patient complex datum generate digitise interpret drive well decision drug development tumour mutational burden codevelope fmi enable patient empowerment improve understand immune biology technology empower patient give ultimately help match therapy control health example enable combination people likely benefit selfmanagement provide information connect patient monitor enhance treatment modern diagnostic tool include pointofcare adherence testing connectivity datum remote monitoring disease potential improve treatment health app sensor digital biomarker provide outcome disease management early rich source information datum tracking detection example online platform digital improve convenience example roche diabete management help healthcare provider develop app continuously measure symptom well fast therapy decision fluctuation parkinson disease patient improve communication patient roche need visit clinic launch navify tumor board solution clinical workflow decision support software future individual well inform optimise decisionmake cancer patient case genetic profile disease review clinic socalle tumour board availability appropriate therapy match multidisciplinary team meeting specific condition economist intelligence unit world industry outlook healthcare pharmaceuticals june european society medical oncology congress september madrid spain efficiency technology enable timely accurate diagnosis treatment improve success rate minimise unnecessary treatment result significant efficiency gain usage resource available optimise addition roche utilise digital technologywhether revamp conduct clinical trial use datum change register new productsto efficient roche effort digitisation continue commitment further benefit product service bring patient hand hand work currently ongoing try well understand science interpret datum quick use new technology end goal bring innovative treatment right patient fast business model innovation ensure continue provide innovative product service patient invest onefifth sale research development rd activity year thank focus science area high unmet need expertise pharmaceutical diagnostic roof successful introduce new medicine different disease indication navify tumor board software support decisionmake optimise therapy patient new diagnostic test instrument cancer service late additionally broad exciting pipeline pharmaceutical diagnostic division invest today bring hope tomorrow focus therapeutic area significant contribution society include disorder central nervous system alzheimer disease autism aremarket environment roche roche develop new medicine conduct study need high level investment diagnostic advance vision disease see major integrate core laboratory broad range diagnostic test fully automate process progress decade roche innovate area unmet need develop new medicine disease major progress decade include medicine generic biosimilar support bladder cancer tecentriq multiple sclerosis ocrevus financial sustainability healthcare system giant cell arteritis actemraroactemra approve fda november hemlibra offer immense total drug include potential improve quality life model list essential medicine haemophilia pointofcare cobas liat system roche medicine widely available test provide precise test result rapidly time benefit large number people billion essence patient survival people treat roche antibiotic bactrim introduction example value innovation patient treat generic major advance science datum technology version similarly foundational polymerase chain aid development increasingly sophisticated reaction pcr technology develop roche treatment option disease like cancer efficient way copy amplify small segment immunotherapie combination therapie real dna rnastill benefit million people value innovation realise actually patent expired reach benefit patient need roche actively work payer government regulator globe implement develop flexible pricing solution facilitate flexible procedure review approve public reimbursement assistance programme truly innovative medicine fast breakthrough help patient access treatment therapy designation prime eu significantly reduce lead time lifesave patent protect intellectual property allow drug help roche recover investment product portfolio commercial exclusivity fast enable investment additional limited period time recover investment area include study rare disease research development benefit spinal muscular atrophy erdheimchester disease necessary innovation premium business enterprise patent medicine expire innovation generate value develop innovation represent continue benefit society product advance standard care disease biosimilar generic available lower significant unmet need able meet cost increase number patient obligation shareholder society treat open competition originator number december prime priority medicine scheme launch european medicine agency ema enhance support development medicine target unmet medical need ear shareholder despite rapid medical scientific advance treatment individual patient short cure common illness possible time alzheimer disease million people world access basic healthcare infectious remarkable progress division attributable disease believe eliminate fact chf billion prove resistant treatment invest research development backdrop measure success healthcare company strength business year term extent find innovation reflect good financial result solution urgent medical problem sale chf billion core operating profit chf billion decrease net income past year significant accordance ifrs extraordinary item progress drug development roche receive amortisation impairment breakthrough therapy designation medicine new compound time recent year effort vain product fail designation offer prospect reach people need work fast approval award health year improve access healthcare authority fda initial clinical trial datum exhibit world abundantly clear promising efficacy disease roche lead dialogue cooperation involve industry term indicator innovative affected bring last improvement strength important systematically address limit factor inadequate infrastructure give rapid pace datum volume education lack disease awareness grow digital decisionmake tool significant problem lack basic health increasingly important medical practice insurance jointly partner consequence roche diagnostic ge healthcare extend introduction private insurance recently enter longterm strategic partnership policy cancer treatment china focusse develop comprehensive digital asian country time work platformsinitially oncology intensive care supervisory authority government medicinesto support doctor identify good industry combat new threat antibioticchairman shareholder letter roche abundantly clear collaboration involve bring last improvement concern access resistance development new type propose dividend increase swiss franc diagnostic product medicine share nonvoting equity security annual general meeting subject approval task require patience st consecutive dividend increase stamina sustainability long important component business strategy pursue offer thank work integrate approach want achieve medical advance constantly improve therapeutic standard improve access medical care thank employee work improve access product tireless dedication past year chairman video take social responsibility crucial area offer shareholder heartfelt thank rochecomme environmental protection supply chain trust place corhtm employee retention delight diverse sustainability effort reward ninth consecutive yearwith rank dow jones sustainability indices look successful year believe roche positioned continue contribute medical solution efficient dr christoph franz healthcare environment innovation chairman growth rate report constant exchange rate cer average board director roche board director bernard poussot c e dr christoph franz chairman c e dr severin schwan f prof dr richard p lifton c e julie brown b e dr claudia suessmuth dyckerhoff b e anita hauser e paul bulcke b e prof sir john bell b e dr andreas oeri representative shareholder group pool voting right e andr hoffmann vicechairman representative shareholder group pool voting right c e peter r voser c e corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche board director december ear shareholders successful year rochein term fdahas prove superior establish treatment financial result certainly especially method furthermore late result important development new medicine diagnostic product trial pioneer field cancer immunotherapy great news look demonstrate potential tecentriq past year solid basis face treatment type cancer future confidence lay groundwork drive forward delivery personalise healthcare immunology play significant role solution actively help shape change growth diagnostic division healthcare sector expand fully automate immunodiagnostic portfolio bring step close integrate exceed growth target division core lab help central laboratory gratify growth efficient competitive pharmaceutical division come new product ocrevus tecentriq alecensaand show digitisation healthcare give opportunity consistently achieve goal renew fast progress area personalise portfolio regionally experience particularly healthcare analysis realworld dataanonymise strong pharmaceutical sale growth patient data visit doctor medical record diagnostic division sale show especially sharp sourceswill major boost rise china innovation medium long term diagnostic product billion test especially please able conduct million patient introduce new product area significant treat medicine year medical need recent approval ocrevus take clinical trial want example give patient multiple sclerosis access well use underlie wealth datum effective treatment hemlibra innovative crossdivisional research development haemophilia treatment close major gap activity require close collaboration treatment blood disorder prevent healthcare provider health insurer authority halt bleed adult young people child continue expand partnership recent trial hemlibragiven fasttrack approval world past yearceos shareholder letter roche growth new product demonstrates consistently achieve goal renew portfolio midst change thing constant sale expect grow stable lowsingle importance employee company digit range constant exchange rate core earning past year show high degree flexibility share target grow highsingle digit passion help shape future ninety percent constant exchange rate exclude tax reform employee worldwide participate internal impact core earning share target grow employee survey eightytwo percent say broadly line sale roche expect proud work roche confirmation increase dividend swiss franc incentive continue effort ceos video preferred employer attract retain well like thank value shareholder rochecomme talent industry trust place company corhtm year transition long foresee expect competition biosimilar cancer medicine mabtherarituxan herceptin mainly europe initially time systematically renew portfolio innovative product challenge multiplying believe position successfully overcome thank dr severin schwan ongoing strength medical innovation chief executive officer growth rate report constant exchange rate cer average corporate executive committee roche corporate executive committee dr stephan feldhaus head group communications dr alan hippe chief financial officer osamu nagayama chairman ceo chugai dr gottlieb keller general counsel roland diggelmann ceo roche diagnostic cristina wilbur head group human resource daniel oday ceo roche pharmaceutical dr michael varney head genentech research early development gre dr severin schwan ceo roche group dr sophie kornowskibonnet head roche partnering prof dr john c reed head roche pharma research early development pred member enlarge corporate executive committee roche corporate executive committee december business performance roche bu sine pe r mance recently launch medicine contribute strongly growth topselle product continue doubledigit sale increase material topic cover chapter product portfolio strategy growth strategy emerge develop market contribution un sdgs g ood result division group sale rise chf billion solution main contributor lead core operating profit grow reflect strong growth immunodiagnostic business underlie business performance core ep increase regional term growth drive asiapacific ifrs basis net income decrease continue strong growth china ifrs result include charge impairment sale increase europe middle east africa goodwill intangible asset amortisation emea latin america stable intangible asset north america sales pharmaceutical division increase approval line extension pharmaceutical chf billion recently launch medicine fda approve new medicine ocrevus tecentriq alecensa contribute ocrevus treatment relapse chf billion new sale represent primary progressive form multiple sclerosis division growth perjeta continue strong hemlibra people haemophilia sale increase growth partially offset factor viii inhibitor low sale tarceva avastin course year health authority approve sale advance lead ocrevus number new indication exist product tecentriq xolair mabtherarituxan europe december fda approve perjeta sale decline mainly low mabthera combination herceptin chemotherapy rituxan sale drive competition biosimilar adjuvant surgery treatment herpositive international region sale grew lead early breast cancer high risk recurrence latin america asiapacific subregion japan approval base result phase iii aphinity sale increase main growth driver study approval grant alecensa alecensa anaplastic lymphoma kinase alkpositive non small cell lung cancer nsclc gazyva diagnostic division sale increase untreated advanced follicular lymphoma chf billion centralised point carebusiness performance roche development pipeline good progress show approval new medicine line extension positive result clinical study key area highlight include datum study cancer immunotherapy clearly reflect potential tecentriq treat different kind cancer europe key approval grant course connectivity automation laboratory year include alecensa monotherapy new instrument support effort expand core firstline treatment previously laboratory consolidate integrate wide range treat alkpositive advanced nsclc platform cover diagnostic discipline molecular diagnostic lab coagulation january ocrevus approve eu haematology pointofcare testing treatment relapse primary progressive form multiple sclerosis chmp approach support expand recommend approval hemlibra exist broad test portfolio additional new test include cobas liat system test integrate diagnostic solution rapid identification lifethreatene infectious course year new key instrument disease healthcareassociate infection methicillin launch allow increase resistant bacteria viral infection growth rate report constant exchange rate cer average ales diagnostic division grow strongly chf billion centralised point care solution hiv testing impact low sale hcv test large contributor division sale growth base effect strong hcv test sale integrate serum work area solution comprise immunodiagnostic clinical chemistry tissue diagnostic sale increase drive segment main growth driver advance stain primary stain portfolio grow respectively companion sale molecular diagnostic increase sale diagnostic business grow human papillomavirus hpv screen blood screen business grow diabetes care sale decrease affect challenge respectively virology sale stable growth market condition particularly north america topselle product portfolio chf million cobas cobas ventana cobas accuchek immunodiagnostics clinical chemistry advance stain virology diabetes care business performance roche north america europe middle east africa emea japan latin america asiapacific division sale growth drive asiapacific region contribution region vary different level market maturity increase access healthcare diagnostic economic development africa major healthcare solution demographic shift advance science access programme implement technology lead globally increase demand number local government close collaboration diagnostic leader field vitro international organisation diagnostic roche position address unaid partner industry roche support market dynamic public funding constraint initiative sustainable commercial lead consolidation laboratory hospital offer overall diabetes care sale decline result continued price pressure diagnostic region growth see market provider number people diabete continue grow awareness latin america business segment contribute condition need manage adequate growth sale expand diabete care blood glucose monitoring system north america sale growth lead tissue asiapacific region major driver diagnostic roche continue gain market share division growth immunochemistry key laboratory decentralise coagulation contributor china generate half absolute monitoring segment recently launch product sale growth market region continue important new business development volume growth expand access testing offset low sale diabetes care business diabete care sale fall continue price pressure sale increase emea region drive sale growth japan drive centralised core laboratory business contribution market point care solution diabetes care sale decline growth rate report constant exchange rate cer average diagnostic medical value improve health empower laboratory leadership cobas e module receive fda develop new integrate diagnostic approval expand system success market solution design address challenge today launch strengthen anticipate need tomorrow key icl solution cobas e module offer high expand core laboratory consolidating value flexibility design high integrate wide range platform cover throughput continuous operation diagnostic discipline molecular diagnostic time reduce waste lab coagulation haematology pointofcare testing integrate core lab icl vastly expand launch avenio ctdna analysis efficiency scope quality diagnostic kit portfolio nextgeneration sequencing capability laboratory ngs liquid biopsy kit oncology research kit detect mutation class high sensitivity january cobas new dedicated kit researcher profile genomic haematology testing solution available complexity different cancer stage tumour country accept ce mark mark type obtain result day avenio entry haematology diagnostic market millisect system tissue dissection instrument cobas provide great accuracy consistency utilise automate digitallyassiste process result identify counting isolate reliably efficiently isolate clinically relevant cell categorise abnormal cell patient sample testing commercially available july automation digitisation reduce need resourceintensive manual microscope review diabetes care business aim enable well allow quick delivery result ultimately management diabete major healthcare burden aids patient diagnosis focus integrate diabetes management increase time range people diabete acquisition mysugr gmbh austria june key roche integrate core lab vastly execute diabetes care strategy expand efficiency quality acquisition viewics inc november allow roche expand leading position customer diagnostic capability icl business analytic capability enablingbusiness performance roche laboratory fast datadriven informed decision operation process december enter strategic longterm partnership ge healthcare jointly develop comarket digital clinical decision support solution partnership initially focus product accelerate improve personalise treatment decision patient cancer critical care ge healthcare aim develop industryfirst digital platform allow seamless integration analysis patient record realtime datum medical roche offer broad range test women health include area fertility good practice late research outcome bone health cancer women health improve access healthcare mean woman april receive k clearance fda world benefit enhance cintec histology test test disease prevention improve screening approach clinically validate p biomarker test help well diagnostic test roche currently pathologist determine woman receive offer comprehensive range test cover fertility treatment cervical precancer test pregnancy bone health breast cancer ovarian cervical cancer portfolio include cancer cervical cancer february launch cobas hpv test cintec plus cytology test elecsys amh plus immunoassay available ivd test cintec cemarke companion test fertility therapy histology test perform benchmark ihc ish series instrument confirm march launch ivd cobas hpv test presence absence highgrade cervical disease cervical cancer screen cobas woman tissue biopsy system country accept ce mark p biomarker enable conclusive diagnosis hpv dna assay give laboratory ability provide distinctive visual confirmation pre run hpv dna test simultaneously cancerous cervical lesion missed previously release cobas infectious disease assay hematoxylin eosin interpretation ce mark certification mark indicate conformity eu wwwwhointmediacentrefactsheetsfsen infectious disease test expand broad portfolio infectious disease represent grow infection life threaten global threat announce world people solid organ transplant develop run effective antibiotic fight increasingly symptomatic cmv infection cobas cmv test resistant bacteria highly efficient standardise international standard automate test provide accurate diagnostic improve harmonisation cmv testing result play critical role prevent overuse healthcare institution addition cmv antibiotic help health system control assay cobas system comprehensive test spread infectious disease menu include viral load assays hiv hcv hcv genotype hbv april launch cobas liat system infectious disease assay ce markets july cobas liat system menu expand cobas liat system offer realtime pcr ce launch cobas mrsasa test nucleic acid test detect clostridium difficile qualitative detection differentiation minute timely accurate diagnosis methicillinresistant staphylococcus aureus mrsa infection vital major cause staphylococcus aureus sa point care healthcareassociate infection hai quickly million people carry mrsa life threaten especially highrisk patient commonly identify antibioticresistant elderly compromise immune pathogen europe patient system undergo antibiotic treatment develop mrsa infection year result cobas liat assay represent breakthrough patient million excess day hospitalisation traditional diagnostic method eur million extra inhospital cost design hour result deliver clinician support rapid screening surveillance mrsa cobas liat cdiff assay hai portfolio sa cobas liat system ideal use expand exist diagnostic menu available emergency setting intensive care unit cobas liat system include respiratory conventional testing method assays cobas strep influenza ab rsv hour turn culture result cobas liat system testing take minute june receive approval cytomegalovirus admission surgery reduce cmvviral load test cobas system risk transmission hospital country accept ce mark transplant july launch cemarke hivhiv patient cmv common viral qualitative test use fully automatedbusiness performance roche cobas plasma separation card global access programme help expand access diagnostic country hard hit hiv underscore commitment provide lifesave diagnostic fight hiv aid allow test area transportation lab week cobas system allow healthcare commercially available test detection professional optimise treatment option zika virus rna sample human plasma intend use screen blood donation september announce plan immediately newly approve cobas zika test initiate screen blood sample cobas alongside routine test screen babesia test investigational new drug blood plasma donation application protocol perform cobas systems test screen direct detection december roche launch cobas plasma babesia dna rna blood specimen separation card innovative technology easy individual blood donor commonly transmit sample collection utilise gold standard human bite infected tick plasma sample type small blood babesia parasite transmit blood collect specially design card blood collection transfusion mother foetus infect sample transportation simplify resource destroy red blood cell potentially lead anaemia limited setting plasma relate lifethreatening complication people separation card remain stable extreme heat compromise immune system humidity provide result correlate plasma viral load standard care meeting october fda approve cobas zika test decision requirement use cobas system cobas zika test wwwwhointmediacentrenewsreleasesrunningoutantibioticsen kock r et al euro surveill business performance roche alan staple clinton health access initiative partnership help change world attitude viral load testing join clinton health access initiative hiv status receive treatment chai year ago work executive people treatment virally suppress contract research industry focus reduce time market new drug prior launch programme well management trial demonstrate quarter patient lowerincome country drug safety efficacy feel truly motivate access viral load testing number life save cut month year development process start project viral load testing consider expensive complicated head global market team infrastructure place transport chai address similar challenge process sample assumption work global regulatory prove wrong production financial system highquality infrastructure cuttingedge technology medicine diagnostic patient lowerincome country affordable sustainable price partnership roche helped change global footprint chai work partner like world attitude viral load test roche company worldwide reach develop world transformative impact global collaboration funder public health problem change recom mendation previously not recommend viral load test successful longterm collaboration patient collaboration roche area hiv go year pioneer early goal include viral load testing infant diagnosis routine programme hiv diagnostic evolve currently infant test not mention year ago key year set global access programme measure programme success result contribute unaid goal standard viral load testing place word people live country like switzerland hiv know status people lowerincome country ale pharmaceutical division increase chf billion largely drive growth recently launch medicine herceptin perjeta kadcyla combine drive immunology international herpositive breast cancer herpositive region sale europe affect metastatic gastric cancer herceptin herceptin market entry biosimilar sale lead growth brazil perjeta sale grow region follow avastin advanced colorectal breast lung increase demand neoadjuvant metastatic kidney cervical ovarian cancer relapse setting sale kadcyla increase glioblastoma type brain tumour sale decline largely increase use cancer mabtherarituxan form blood cancer immunotherapy medicine lung cancer sale rheumatoid arthritis certain type vasculitis continue grow international region sale continue rise increase record key growthdriving product chf millions mabtherarituxan herceptin perjeta actemraroactemra xolair oncology immunology oncology oncology immunology immunology business performance roche sales europe affect removal gazyvagazyvaro chronic lymphocytic reimbursement breast cancer france leukaemia cll rituximabrefractory follicular lymphoma previously untreate advanced actemraroactemra rheumatoid follicular lymphoma sale expand region arthritis form juvenile idiopathic arthritis product launch giant cell arteritis sale growth report region support steady growth demand recently launch medicine subcutaneous formulation ocrevus chf million approve country experience continue strong demand xolair chronic idiopathic indication tecentriq chf million urticaria allergic asthma growth drive approve country alecensa chf million demand indication approve country show good uptake continue strong sale growth japan activasetnkase thrombolytic clotbusting november hemlibra chf million launch agent acute ischaemic stroke sale increase promise uptake drive broad use hospital high number treat patient key growthdriving product chf million activasetnkase kadcyla ocrevus tecentriq alecensa cardiovascular oncology immunology oncology oncology growth rate report constant exchange rate cer average applicable regional performance growth drive brazil china medicines demand foundation medicine market continue area significant service increase service opportunity despite increase complexity drive broadly available europe seek rise competitive pressure dynamic regulatory personalised cancer care level region environment shift valuebase healthcare contribute overall pharmaceutical model overall performance market business sale perjeta actemraroactemra characterise new product launch include remain robust region performance ocrevus hemlibra receive impact decline sale mabtherarituxan breakthrough therapy designation btds avastin biosimilar competition mean award total btds reimbursement reduction respectively fda establish programme addition fda grant seven priority review japan fuel strong sale new exist sale grow alecensa sale increase sale medicine record growth tamiflu actemraroactemra account total pharmaceutical business growth partially offset low sale sale growth largely drive ocrevus tecentriq established product chugai contribute xolair mabtherarituxan overall pharmaceuticals business europe international region work number stakeholder recent year latin america see stable european national level develop solution growth allow government spend ensure sustainable healthcare system healthcare significant challenge timely equitable access innovative remain landscape mark barrier medicine payer develop impede access healthcare include low level implement flexible pricing solution disease symptom awareness late diagnosis weak aim support fast access innovative infrastructure inefficient insufficient funding delay adoption innovative medicine country latin america face unique challenge fuel strong sale roche commitment varied region partner stakeholder growth driver division develop tailor solution help increase access tobusiness performance roche europe eastern europe middle east africa eemea japan latin america asiapacific eemea latin america asiapacific canada form international region medicine diagnostic test latin america achieve strong result region priority include contribute overall pharmaceutical improve access compete biosimilar business sale growth drive brazil noncomparable biologic prepare launches argentina innovative medicine achieve considerable success accelerate registration asiapacific region sale growth drive timeline medicine tecentriq establish product strategic product new ocrevus available patient launch china herceptin mabtherarituxan country ema approval avastin tarceva list national time market experience order shift reimbursement drug list nrdl market like russia iran lose government tender significant step make medicine biologic negatively impact regional available entire population billion people performance steady entry new medicine country new medicine launch mitigate loss product face biosimilar region include ocrevus tecentriq competition strategic product contribute growth asiapacific region contribute overall perjeta kadcyla topselle pharmaceutical business growth primarily medicine region eemea market drive china taiwan vietnam australia contribute pharmaceutical business challenge key market impact overall performance country eemea region additional option patient new product drive growth recently launch medicine ocrevus tecentriq alecensa launch japan alecensa good start follow approve treatment type lung cancer arrival multiple market ocrevus treatment sale total chf million relapse primary progressive form multiple sclerosis rm ppm meet extremely positive combine new medicine contribute response receive approval march chf billion new sale represent prescription continue increase pharmaceutical division growth drive overall year lead sale chf million growth offset decrease sale product end people phase affect competition treat ocrevus globally continue strong sale increase tecentriq approve topselling product treatment advanced bladder cancer continue doubledigit sale growth example meantime tecentriq approve perjeta represent major advance advanced lung cancer important new cancer treatment patient breast cancer generate immunotherapy treatment option contribute total sale chf billion contribute chf million sale roche conduct large chf million new sale launch number study tecentriq combination usage broaden study result medicine roche market investigational confirm medical benefit additional indication portfolio external partner late fda approve perjeta combination effort improve treatment outcome result herceptin chemotherapy adjuvant number clinical study date demonstrate surgery treatment herpositive early breast significant medical benefit cancer high risk recurrence approval base result phase iii aphinity study actemraroactemra sale increase totalling chf billion xolair sell genentech ocrevus tecentriq alecensa see sale advance chf billion activasetnkase sale contribute division growth chf billionbusiness performance roche new medicine unmet need innovative medicinesactemraroactemra approval tecentriq treatment bladder alecensa hemlibraoriginate research cancer represent major advance people affect laboratory chugai japan member potentially lifethreatene disease roche group bring major advance treatment type market collaboration expert cancer year entire roche group represent major contribution patient physician society ocrevus highly effective treatment option people rm ppm offer favourable benefitrisk profile demonstrate phase iii multiple sclerosis force taekwondo world champion amr khairy wheelchair study despite available therapy people relapse form ms continue experience disease activity disability progressionworsening disability people ppm approve treatment previously experience fast accumulation disability ocrevus give month potential transform therapy form ms approval actemraroactemra giant cell arteritis add list major break therapy disease high unmet need actemra roactemra new treatment option debilitate disease year hemlibra receive fda approval november contribute roche strong history innovation transform medical practice hemlibra bispecific monoclonal antibody design restore blood clotting process people haemophilia factor viii inhibitor administer injection readytouse solution skin weekly clinical development programme look potential help overcome current challenge shortlaste effect exist treatment development factor viii inhibitor need frequent infusionsbusiness performance roche dr amr khairy taekwondo world champion egypt multiple sclerosis patient truly suffer lot initially interested sport like tennis therapy beneficial good take travel globe participate national tennis championship squash taekwondo tournament football finally take taekwondo search treatment attack seriously time continue not talk paralysed study accept faculty medicine not swat fly cairo father surgeon want reward trip america instead ask finally undergo experimental stem cell send korea improve taekwondo skill treatment china train physician olympics seoul understand risk decide proceed go barcelona gold treatment therapy leave confine world championship diagnose wheelchair attack multiple sclerosis kind knock day potential benefit seek attack year risky treatment reverse longterm effect old knock cold not multiple sclerosis far outweigh daily challenge hand leg overwhelmed fatigue disease go china cure surprised fit sportsman visit multiple sclerosis relieve symptom countless doctor egypt direct seek treatment diagnose highlight real need safe multiple sclerosis repute hospital start effective treatment happy treatment take shot cortisone roche medicine approve attack longterm benefit dozen use part world attack later leave continuous seizure numbness body hopefully come egypt soon treatment look therapy involve research funding pray absence treatment god come soon multiple sclerosis option decide look world patient truly suffer lotscience innovation roche sc ie nce innovation translate brilliant idea medicine constitute complex value chain diverse activity chapter look step journey material topic cover chapter product portfolio strategy rd pipeline strategy personalise healthcare contribution un sdgs deep understanding biology disease step long road create safe effective medicine translate molecule medicine follow page look matter patient call combined creativity example major phase step rd unrelenting perseverance thousand people value chain specialised knowledge broad range area early discovery latestage development identify medical need initiate appropriate manufacture regulatory distribution sale action drug research development rd tackle understand underlie biology trigger multitude variable optimise disease tandem expert roche group shy away create lead compound right quality complexity task search cultivate smart partnership academia medicine truly make difference patient live physician patient industry innovate accelerate clinical trial countless challenge need master develop diagnostic test health app scientist lab translate molecule provide deep insight patient condition medicine demand high degree crossfunctional doctor good decision patient teamwork company external partner blaze new trail medical sciences mean push boundary knowledge navigate unfamiliar terrain standard textbook exist provide guidance identify medical need setback failure process discovery antibiotic start penicillin learning derive disappointment rightly consider great medical ultimately propel science ahead result achievement th century breakthrough medicine miraculous quality medicine increasingly lose lustre rapidly mutate pathogen roche investigate disease diverse area acquire resistance widely antibiotic oncology neurodevelopmental neurodegenerative challenge multidrugresistant superbug condition ophthalmology immunology inflammation address conjure regular infectious disease interval public debate accord estimatesscience innovation roche medical need understand biology smart partnership create lead compound innovate clinical trial diagnostic test health app discoverytodelivery value chain deliver value link chain work perfection chapter take look selection interesting molecule innovative technology key phase approach major step million people project die untreatable starting line commitment bacterial infection weaken hospitalise roche begin extensive effort develop new antibiotic patient suffer underlying disease launch diagnostic test cobas prone healthcare associate infections hai liat system rapidly identify mrsa hai cause bacteria spread multidrugresistant strain bacteria methicillinresistant staphylococcus aureus reentere antibiotic space mrsa carbapenemresistant enterobacteriaceae roche significantly step effort hardtoeradicate pneumoniacause streptococci space year revive strong legacy recognise health antibiotic research culminate authority worldwide crisis public health launch bactrim rocephin emergency demand combine effort multiple alliance barda industry declaration player industry hospital university amr support internal rd activity government physician patient problem tackle successfully address unmet need addition promising preclinical create new medicine able cure severe compound roche antibacterial early multidrugresistant infection represent clinical development nacubactam severe hardto valuable contribution society treat gramnegative enterobacteriaceae infection antibodyantibiotic conjugate aac unprecedented effort rochealong treatment mrsa aac use breakthrough company industry associationssigne technology previously oncology set industry declaration antimicrobial resistance antibody tag specific bacterium amr world economic forum davo deliver antibiotic right infect cell follow adoption action compartment activate attack plan number pharmaceutical company bacteria include roche later year nacubactams dual mechanism action roche announce enter roche inlicense nextgeneration betalactamase multiyear strategic alliance barda inhibitor nacubactam meiji seika biomedical advanced research development pharma fedora pharmaceuticals potent authority department health human inhibitor bacterial betalactamase enzyme service barda broad spectrum antimicrobial make ineffective antibiotic programme aim engage industry partner right inhibit bacterial cell wall synthesis effort jointly combat rise antibiotic resistance development plan nacubactam foresee development new medicine administer hardtotreat gramnegative diagnostic test enterobacteriaceae infection recently spread intensive care unit europe fda give molecule fasttrackscience innovation roche designation endorse accelerate development plan make medicine available physician patient early summer patient recruit roche phase study patient complicated urinary tract infection accelerate development plan mean programme pivotal registration trial directly understand biology disease human body liken machine mindboggling complexity currently available antibiotic increasingly lose effect rapidly mutate pathogen work miraculously thing awry acquire resistance increasingly bacterial infection lifethreatening disease cause disease research scientist call understand target repair underlie malfunction error result single miss gene specific cell immune include standard research technology system overdrive innovative imaging method sequence gene combination diverse factor go amiss new way collect analyse deep datum refer big datum suitable target identify precise biological origin disease therapeutic intervention identify potential diseasemodifying target hunt design right molecule start intervention step modern discovery help automate highthroughput screen medicine roche approach prove stateoftheart computeraide molecular modelling valuable oncology neuroscience ophthalmology thousand chemical molecule create rare disease albeit recent test short time target identification consistently roche immunology research represent start activity development traditional treatment approach immune antibodie different method mediate disease focus suppress procedure apply case lead compound immune system roche contrast aim find finally choose undergo iterative molecule finetune system restore multidimensional optimisation achieve good immune balance balance dose exposure effect efficacy ultimate goal find compound target identification ground number well possible active structure fit intend different approach technology target perfectly tolerate highly effective wwwunorgpressengadochtm molecule optimisation sma medicine remain body long spinal muscular atrophy sma neuromuscular achieve medical purpose main challenge disease cause miss mutate single gene human gene alternatively call survival motor neuron smn encodes splice depend correct splicing smn protein protein nerve cell specific function task investigate spinal cord survive result muscle potential target differentiate weakness atrophy sma frequent spare critical gene result effort monogenetic rare disease lead cause publish journal science nature infant mortality communication molecule rg receive fasttrack designation fda april healthy people smn gene efficient small molecule rna splicing modifier make sufficient amount fulllength protein lead test efficacy phase iii clinical trial normal motor neuron function patient affect sma gene miss critically important smn protein absent evolution create backup gene rescue gene call smn similar smn gene gene rna splicing create lead compound right quality machinery act differently smn gene new technology enable scientist well understand translate truncated unstable protein root cause disease especially cancer increase result granular insight vast varied landscape smn protein human need produce causative disease factor cancer bring creation potentially gamechange new therapy roche take challenge research project big step close realisation strike example advance rare disease novel treatment modality new class personalise portfolio time oral smn splice cancer vaccine pcv specifically tailor modifier treat sma move forward tumour individual patient take hopefully help child devastating disease personalise healthcare level german deep understanding disease biology major biotech company biontech develop novel mrna prerequisite smn alternative splicing programme vaccine approach genentech member roche start patient organisation group sign strategic collaboration biontech sma foundation initiate discovery programme september codevelop platform company ptc therapeutic november roche gain exclusive worldwide licence attempt develop therapeutic cancer vaccine discovery programme course year target selfantigen tumour notoriously molecule undergo optimisation step unsuccessful past cancer cell safety efficacy scientist greatly improve regard self immune system molecule ability access difficult area body scientist identify different type tumour brain ensure potential antigen call neoantigen encode byscience innovation roche time oral medicine acquire mutation neoantigen present immune system see nonself move forward hopefully help foreign tumour neoantigen unique patient molecular fingerprint tumour child sma identify sequence tumour genome exact fingerprint derive analysis develop vaccine pcv platform develop biontech design deliver unrivalled expertise protein engineering mrna code unique neoantigen mabtherarituxan launch lipoplex formulation allow intravenous genentech time company administration inject mrna deliver biotechnologically produce monoclonal antibody immunepresente cell process present give true hope people cancer decade neoantigen immune system cell later roche group portfolio highly recogniseand teach target destroy differentiated biologic recognise tumour express tumourspecific neoantigen antigen leverage bodys immune system fight disease act transport protein emergence personalise vaccine deliver instance toxic payload directly biontech possible thank specific target cell combination stateoftheart genomic sequence modern bioinformatic grow gazyvagazyvaro introduce leverage new understanding cancer biology emergence technology design controlling type cancer immuno therapy field enthusiasm sugar molecule specific region antibody neoantigenbase vaccine spur affinity antibody immune effector cell observation patient high neoantigen increase trigger death cancerous cell burden respond well checkpoint inhibitor effectively tecentriq personalised neoantigen vaccine biontech potential broadly scientist roche group continue combine roche cancer immunotherapy effort broaden toolbox physicians portfolio research programme patient fight cancer develop new class consider wave immunotherapy anticancer medicine cancer immunotherapy example new antibody create july journal nature publish result engage immune cell kill tumour cell eliminate biontech study mrnabase vaccine cell suppress immune response generate test carefully select melanoma patient immune cell recognise tumour cell time patient remained promise new cancer immunotherapy platform tumourfree month late include cell bispecific antibody engineer patient phase study vaccine target different antigen solid bloodbase rg combine tecentriq solid tumour haematological tumour naryshkin n et al science sivaramakrishnan et al nature communication sahin u et al nature antibody format hold promise specific cancer setting terms combination trial approve cancer immuno therapy tecentriq smart partnership academia industry researcher face huge complexity medical science today impossible master challenge example term lung cancer segment different molecular subtype drive distinct set genomic driver require distinct set new bloodbase assay development ultimately help tailor treatment option tailor treatment approach add abundance specific immune biology individual tumour target investigational compound available setting confront limitless choice view naturally limit resource single company collaboration diverse diversity approach bispecific antibodie partner essential currently develop cell bispecific antibodie target cd protein express seek secure new firstinclass bestin surface b cell type white blood cell class opportunity address unmet medical need phase clinical development remit partner unit roche pharmaceutical diagnostic division cd cell bispecific tcb base complement strengthen respective internal structural format engineer rd organisation search transformative antibody fragment fab region bind cd technology therapie fab region bind cd protein play role cell activation contrast roche pharmaceutical engage cd celldependent bispecific tdb structure partnership worldwide year fab region target cd new collaboration seal significant proportion fab region target cd antibodie division sale pipeline result potential longterm differentiator partner project goal collaboration haematology provide level clinical successfully leverage combine strength benefit patient b cell malignancy internal external stakeholder ensure mutually current anticdtargeting antibodie new beneficial partnership ultimately help patientsscience innovation roche advance personalisation oncology example collaboration agreement sign roche gns healthcare innovate accelerate clinical trial june roche use gns technology ref emergence entirely new class drug reverse engineer forward simulation opening hitherto close door highly target analyse massive volume proprietary data treatment option stagger combination regimen electronic medical record nextgeneration development call unconventional sequence datum realworld datum approach clinical trial spacefrom collaboration aim generate unique insight recruitment selection trial participant unravel hidden driver drug response cancer identification validation novel endpoint progression challenging cancer neuroscience central nervous system disorder cdpositive diffuse large b cell lymphoma roche develop strong position hope find new personalise nextgeneration rd year factor cancer treatment address challenge complicate exact diagnosis disease setup meaningful trial protocol establish strategic alliance foundation medicine fmi roche announce positive result cancer tissue biopsy take new assay jointly develop reveal molecular underpinning company september aim advance example specific genetic mutation contrast personalisation cancer immuno therapy capture neurodegenerative disease alzheimer subsequently leverage progress biomarker disease neurodevelopmental disease science ultimately help tailor treatment option autism spectrum disorder affect brain specific immune biology individual evident biopsy take directly tumour facilitated novel assay btmb fortunately alternative method different bloodbase tumour mutational burden quantitative imaging technology allow reveal glance clinical marker measure number mutation brain effective tumour genome oncology clinical trial certain objective btmb biomarker study conduct endpoint change time measure plasma sample pivotal phase ii poplar tumour shrinkage overall survival phase iii oak tecentriq study tmb find correlate indicative collaboration diverse partner likelihood progressionfree survival benefit immuno therapy tecentriq tmb essential master todays complexity measure tumour biopsy testing approach possible medical science extend tmb testing significantly patient gandara r et al european society medical oncology esmo congress september madrid spain progressionfree survival neuroscience clinically meaningful change autism area identification validation medicinal chemist roche groundbreaking endpoint difficult require innovative work vasopressinreceptor antagonist start think collaborative approach ultimately succeed create small molecule rg balovaptan image tau pathology alzheimer disease fastforward molecule tau pathology hallmark alzheimer disease investigate latestage pivotal trial treatment ad certain neurodegenerative disorder individual autism spectrum disorder asd ad postmortem study suggest common neuro developmental condition specific location tau pathology brain characterise difficulty social correlate type cognitive symptom interaction communication hitherto overall disease severity present life behavioural cognitive treatment valuable able detect tau pathology available people autism people live ad order assess disease progression support therapeutic clinical trial discover design optimal molecule radiochemist roche identify small molecule major achievement selectively bind tau pathology amenable go clinic assess molecule radioisotope labellingenabling use positron efficacy potentially improve core social emission tomography pet detect tau people communication challenge face people live ad autism big challenge measure change context demonstrate lead tau pet tracer currently evaluation balovaptan improve adaptive behaviour phase observational study study patient need everyday life sure ad undergo imaging tracer positive change clinically meaningful month preliminary datum suggest patient caregiver authority technology sensitive disease progression warrant significant investment require novel valuable technology latestage development incorporate ad trial portfolio roche group include trial crenezumab roche scientist investigate vineland adaptive gantenerumab ro antitau behaviour scale robust useful tool quantify social behaviour communication skill impact daily living collaboration key player field international consortia cns area identification academic institution major foundation patient advocacy group roche scientist collect data validation endpoint require approximately vineland adaptive behaviour scale result apply rigorous statistical innovative thinking approach method estimate threshold numbersscience innovation roche positron emission tomography pet enable scientist detect tau people live ad time point leave right month scan patient axial plane indicative minimal change agree aggregate alphasynuclein firstinclass molecule meaningful time behavioural target underlie pathology pd halting scale place clinical trial infectionlike spread neuronal death pd short base successful work roche progressive degenerative disorder central nervous recognise researcher system cns affect people age scientific community patient group characterise neuronal accumulation set new standard progress clinical aggregate alphasynuclein cns result research area asd january balovaptan wide spectrum worsen motor symptom receive fda breakthrough therapy designation rest tremor muscle stiffness walk difficulty balance problem current clinical assessment standard movement disorder society unified parkinson develop diagnostic test health app disease rating scale mdsupdrs rely june roche announce start phase ii physician testing patient scale include study codevelope prothena anti ask patient perceive severity alphasynuclein antibody rg parkinson detail happen clinic visit disease pd area high unmet need lack largely unknown roche scientist design app diseasemodifye treatment bind integrate assessment suite remotely pharmaceutical clinical pipeline phase phase ii phase iii registration oncology inflammation immunology neuroscience infectious disease ophthalmology pipeline new molecular entity nme cover broad range disease highly innovative technology apply create produce active molecule measure capture motor symptom pd patient outstretche hand phone accelerometer continuous monitoring smartphone record hand movement passive monitoring pipeline clinician equip sensitive register signal gait activity mobility rochecompipeline comprehensive outcome datum patient interaction accelerometer gps possible oneoff testing short visit sensor picture patient daily activity neurologist clinic ultimate goal capture far walk sit vast amount datum fast reliably monitor value extract massive datum individual treatment response subsequently set apply machine learn toolbox allow personalisation treatment algorithm capable provide interpretable result study sensor detect significant apply machine learn large datum set rest tremor patient clinically score active test register signal tremor dexterity tremor basis encourage result balance instance check impact target alphasynuclein rg level tremor patient hold phone impact disease progression measuredscience innovation roche nextgeneration parkinson app plus review information smartwatch evaluate global phase ii disease manifest patient study start june result experience daytoday development obtain far highly promising point bring disruptive change research develop great potential digitisation healthcare approve pay medicine connect past future fda grant roche historically roche productive breakthrough therapy designation btds bring important medicine patient fact expedite development review medicine medicine develop roche include early evidence potential clinical benefit model list essential medicine ample lifethreatening disease roche lead proof twentyfive patentfree industry term number btds bear include lifesave antibiotic antimalarial witness innovative power roche worldwide cancer medicine rd effort clearly reflect value product patient society large recent history prove roche continuous massive investment rd totalling roughly year see strong flow positive news onefifth sale chf billion group roche regulatory approval important new level large single rd budget medicine ocrevus hemlibra life science industry large positive datum key clinical study alur industrieshas bear rich fruit alex impower nonsmall cell lung year roche new molecular entity cancer kidney cancer pharmaceutical rd portfolio test haemophilia major highlight hundred early latestage clinical trial year positive development temper number medicine launch trial fail meet primary endpoint time higher previous positive result clinical seven year trial approval new medicine represent strong validation pipeline time continue legacy draw world major change industry class pharmaceutical diagnostic capability complement solid expertise area generation sequence actionable realworld clinical datum roche uniquely position positive development report personalise healthcare level represent strong validation era digital technology able increasingly tailor medical treatment need pipeline individual small subgroup patientsaccess healthcare roche acce healthcare groundbreaking advance medical science meaningful reach people need material topic cover chapter sustainable healthcare pricing disease awareness treatment education growth strategy emerge market contribution un sdgs w e develop comprehensive access plan adjust local requirement embed business strategy accord million people lack join force difference access basic healthcare multidimensional roche play lead role initiative challenge size fit bring lead solution complex treatment biopharmaceutical company cancer require sophisticated diagnosis world bank union international cancer specialised training hospital infrastructure control uicc access accelerate initiative successful therapy barrier differ launch focus improve country country roche focus locally tailor access treatment noncommunicable disease solution access intricately link ncds cancer cardiovascular disease healthcare system work address chronic respiratory disease diabete multidimensional challenge access take un sustainable development goal focus key area reduce death ncds awareness key pillar initiative commitment diagnosis individual company scale effort healthcare capacity improve access roche launch new programme fund pakistan offer sustainable financial solution need roche oncology order properly address factor immunology biologic medicine detail need deep understanding root cause people access medicine programme conduct kenya diagnostic end systematically apply roche work government access planning framework country country increase access treatment herpositive create comprehensive access plan breast cancer roche support comprehensive embed business strategy date plan address awareness diagnosis detailed plan country healthcare capacity treatmentaccess healthcare roche breast cancer morocco hiv subsaharan africa diabete africaasia prm europe breast cancer usa testing asia breast cancer saudi arabia differential pricing egypt breast cancer colombia elderly care japan financial support usa awareness disease diagnosis disease healthcare capacity need fund healthcare symptom essential complex vital welltraine team work investment reimbursement screening early detection ensure right treatment right medicine test critical choice equipment provide good protect patient chance patient financial burden increase awareness help early detection local government increase successful treatment begin awareness understand cancer impact public symptom disease visit healthcare help improve healthcare fund professional lack awareness patient access care roche run awareness campaign follow agreement key partner build strong partnership world united arab emirate roche support local improve health authority reduce cancer mortality conduct workshop educational impact awareness programme activitie awareness campaign train healthcare demonstrate morocco local roche professional addition roche partnering organisation partner lalla salma foundation stakeholder dubai cancer initiative provide contre le cancer campaign initiate unlimited access screen cancer treatment breast cancer awareness screen programme million people live dubai date free screening provide million woman enable early breast cancer diagnosis hundred successful therapy begin awareness middle east develop breast cancer policy project collaboration symptom disease visit international partner well understand attitude priority cancer region healthcare professional use research develop white paper track universal health coverage global monitoring report june latin america team economist country early diagnosis rare intelligence unit raise awareness impact number african country cancer cancer region presentation patient diagnose latetoend stage war cancer latam conference bogota addition lack general awareness highlight death cancer region hospital clinic simply equip increase well disease instrumentation qualified personnel need awareness diagnosis healthcare capacity funding provide treatment placement partnership collaboration need roche automate ventana benchmark diagnostic equipment tissue diagnosis immunohistochemistry timely diagnosis ensure right treatment choice ihc respective training programme critical diagnosis critical complex require component support access subsaharan specialist laboratory technicians facilities africa ssa date technician testing accessible people train impact disease area proper diagnosis way ensure breast cancer total cancer centre right treatment choice ssa stateoftheart technology early accurate diagnosis significantly increase breast cancer project initiate roche patient chance survival breast cancer turkmenistan enable significant improvement example patient survive year early detection differentiate diagnosis diagnose early compare diagnose disease main pillar project disease advanced stage result introduction ihc diagnostic automate modern diagnosis therapy breast cancer death equipment switch manual system rate drop automate testing allow increase biomarker testing woman include patient regional hospital remote area country result modern diagnosis pillar widespread disease awareness campaign regularly conduct roche support therapy breast cancer death rate drop capital ashgabat region country result increase early breast cancer detection versus access healthcare roche early diagnosis advanced stage breast cancer vast majority patient survive year diagnose early quarter woman survive disease catch late stage diagnostic capability place attend workshop meaningful people clinic test conduct clinical breast examination colombia instance breast cancer cause woman screen overall high number death woman cancer approach serve template year colombian woman aware type cancer risk factor cancer importance early detection diagnosis improve healthcare capacity limited healthcare infrastructuresuch roche work colombia large lack healthcare facility train healthcare healthcare organisation address issue professionalsis major barrier access provide training awareness campaign modern medicine diagnostic create consultorio para la mujer women world poor country help overcome consulting room country barrier roche establish number specialise clinic work improved programme aim make last improvement access early diagnosis improve treatment local capability range educate objective reduce barrier hurdle train healthcare professional regulatory patient encounter way diagnosis personnel helping establish clinic laboratory treatment hopefully recovery possible strengthen local manufacturing capability work health insurance supply chain company healthcare professional provider government far focus increase local capability healthcare professional attend plenary believe provide sustainable way lecture patient journey programme address local health need help develop httpseventseconomistcomeventsconferencesamericaswaroncancerlatam national cancer institute seer available httpsseercancergov statfactshtmlbreasthtml desantis c e et al breast cancer statistic cancer journal clinician doi caac woman undergo rehabilitation activity follow breast cancer surgery healthcare system future example negate need healthcare professional blue tree programme india travel major city attend necessary ongoing present example good practice event medical education dilogo roche reach nd united nations general assembly register physicians seven unga unique cancer patient support country latin america initiative tailor address multiple hurdle patient experience course health infrastructure country africa treatmentprimarily diagnosis affordability capacity meet rise need care adherence project support noncommunicable disease include cancer patient roche partner current healthcare workforce subsaharan africa doctor enable access treatment need scale meet cancer centre india patient exist need help address acute shortage programme show increase therapy oncology healthcare professional roche conduct adherence rate training session oncology specialist region latin america online platform dilogo roche establish healthcare professional enable sustainable healthcare funding region update information develop number pricing solution clinical study scientific advance congresse personalise reimbursement model prmaccess healthcare roche collaboration insurance firm enable pricing accord value medicine bring different indication provide million patient well international differential pricing set price medicine accord countrys economic access cancer medicine situation purchase power parity adjust gdp capita formula example hurdle overcome roche collaboration private insurance company country afford proper cancer care public coverage adequate southeast asia example patient diagnose cancer suffer financial catastrophe die china cancer medicinesherceptin year medical insurance scheme cover mabtherarituxan avastin tarcevawere population africa include national reimbursement drug list nrdl time cancer patient innovative funding solution china access potentially fund barrier exist find practical lifesaving treatment agreement come result way overcome georgia enter roche systematic approach identify local agreement city municipality tbilisi access hurdle create tailor local plan improve fund herpositive early breast cancer patient eligible herceptin uruguay result commercial agreement programme expand include breast cancer countrys national resource fund patient receive perjeta herceptin positive breast cancer patient metastatic setting offer flexible pricing solution access herceptin perjeta kadcyla woman early breast cancer georgia patient expect receive treatment treat herceptin pursue time period effort enable treatment advanced breast cancer patient country order protect patient financial burden fund need investment healthcare pakistan launch patient support programme reimbursement medicine diagnostic test collaboration number partner country provide universal enable provide fund indigent patient healthcare spread risk catastrophic disease eligible herceptin mabtherarituxan avastin population develop perjeta august patient part world country lack coverage able receive potentially lifesave patient turn away debt medicine reachaccess healthcare roche micha nussbaum roche brazil job make contribution community swiss study medicine university look sustainable solution identify zurich interested translate healthcare bottleneck cause lack training scientific innovation patient benefit roche organise course doctor nurse eventually lead interlude business community worker brazil consultant pharmaceutical industry discover woman pick cancer screening result develop interest brazil begin exchange system inform message programme mba study huge mobile phone fascinating country different subculture bring wave immigrant despite current leverage international connection economic crisis underlie dynamism invite expert canadas oncology healthcare reward people initiative persistent policy share good practice congress join roche paulo national public policymaker commission functional expert company focus benchmarking report economist intelligence expand access therapy cancer patient like unit brazil current oncology healthcare policy develop country brazil rise finding present local congress incidence breast cervical colorectal cancer highlight success area improvement partnership brazilian healthcare authority appreciate work public policymaker work roche limited impact partner way help improve access large country collaborate healthcare continue collaboration federal state municipal healthcare authority roche transition pharmaceutical brazil public access manager make new position diagnostic difference example reach agreement state gois maranho expand people brazil feel roche access patient advance oncology treatment longterm commitment global negotiation proceed state local company case personal connection marry brazilian detailed analysis step cardiologist raise child cancer patient journeyfrom prevention convince job screen diagnosis treatment try make contribution communityour people roche people talented individual connect inspire purpose basis success people drive healthcare innovation touch live million patient material topic cover chapter employee engagement talent retention compensationbenefit leadership commitment organisational effectiveness contribution un sdgs special work roche start culture year remain majority core global people practice principle familyowne swiss company commit simplicity flexibility accountability speed innovation focus long term ensure critical component transformation sustainable future generation technology play key role offer ask culture roche employee sophisticated userfriendly option provide describe deeply engraine value integrity people easy system access place courage passion highlight collaboration device time embe mindset thrill working cut edge science require new practice reshape inspiration outstanding leadership way people interact support provide underpin share purpose timely meaningful conversation check patient need people work in dialogue employee manager roche know work contribute breakthrough put conscious focus essential theme diagnostic solution innovative medicine connection capability contribution career treat cancer multiple sclerosis host simple powerful framework foster disease relationship base trust share ownership ensure conversation focus continue receive accolade matter employer create excellent environment people year year headquarters leverage diversity enhance wellbee switzerland roche affiliate world importance mutual respect workplace award mark great place work institute reflect commitment diversity inclusion employer institute respective di major corporation countrie genentech roche europe state di goal publicly recognise highly coveted fortune substantial progress achieve good company work list think physical characteristic quality person unique order innovate people practice leverage diversity engine innovation strive addition push new frontier science inclusive workplace individual innovation present focus respect fully contribute skill people companywide project serve transform experience perspective complement theour people roche support leader global network screening fitness centre workplace ergonomic di champion lead effort site evaluation counsel service year functional area grassroots example dedicate special week roche site globally thing diversity initiative employee collectively focus wellbee heighten overall globally post pledge video awareness importance topic employee positively impact di learn live offer participate activity organise local team range want leadership reflect organisation sport relaxation technique lecture society roche believe health topic nutrition build firsthand knowledge healthcare environment beneficial help expand find desire balance priority access treatment guide life challenge varied person right patient support people gain roche firmly support flexible work arrangement experience live work highgrowth parttime work job sharing flexibility mean develop market mature establish find new way work technology market strengthen capability embed alternative work environment people use video critical understanding conference telepresence engage online community good practice sharing establish corporate goal year ago solve problem virtually connect increase percentage woman leader colleague geography benefit people recently add focus increase percentage environment reduce carbon leader bring experience diverse market footprint progressively introduce work percentage woman leadership role roche environment diverse concept encourage overall rise term leader collaboration enable quiet private space breadth experience achieve foster spirit teamwork innovation initial milestone people importance worklife balance flexibility mean find new healthcare company believe healthy lifestyle major factor overall wellbee way work technology employee basis live roche initiative tailor site good alternative work environment represent need include medical checkup learn leadership development adapt everchange world roche strive help people realise learn development dimension potential contribute high level roche stretch assignment organisation evolve fastchange world challenge employee grow professionally learn integral daily work change perspective temporary assignment emphasise continuous building capability affiliate continent microsecondment future manager partner volunteer work africa case pharma employee ensure impactful action technical operation team represent take support employee learn employee mean learn work professional growth range build efficient way lean manufacture new connection gain new experience reverse mentor different classroom course online learning generation people work learn leadership commitment firmly believe person genuine interest people listen carefully tell truth explain roche deserve great leader empower trust people decision discover develop potential people day strive lead example strive excellence extraordinary result set priority simplify work consistently demonstrate value congratulate people job integrity courage passionour people roche people fiveyear goal base figure representation woman key leadership role representation people establish develop region experience key leadership role quartile rank overall employee engagement score measure global employee opinion survey goal baseline find opportunity leverage new executive leadership development collective strength offer kinesis aptly name represent everchange landscape agility need kinesis njia new kind leadership leadership response change development emphasis traditional instruction believe employee deserve great peertopeer learn personal leader touchstone mean roche introspection solve realworld problem find leadership commitmentscreate collaborative effort company experiencebase leadership development expect leader bring commitment focus njia kiswahili path midlevel manager life daily behaviour expectation undergo intensive week rural tanzania reinforce range learning experience work local counterpart resultsoriente leader lead roche suite programme project expand screen cervical leader organisation cancer participant personal professional impact lifechanging worldclass talent shape future enhance digital capability key reason prospective employee cuttingedge science personalise healthcare join roche choose stay calibre roche sciencedriven company people work awardwinne constantly look talent drive wave scientist pioneer invention expert healthcare breakthrough important trend professional field study attract shape industry deep datum leadership retain world talented people position personalise healthcareuse molecular diagnostic target medicine customise therapy individualwe unique position translate deep datum patient benefit realise new medical paradigm develop applause recognition reflect enhance digital capability people recruit software engineer bioinformatic way work specialist realworld datum analyst machine learn expert digital professional connect purpose recognition job powerful motivator contribute great deal overall work satisfaction roche umbrella codelife roche launch number award extraordinary achievement code game career website engineer addition implement innovative programme know present coding skill goal game applause encourage peertopeer recognition employee equip laboratory produce medicine patient send colleague world customise thank ultimately attract talented digital professional note nominate point redeem roche winner receive opportunity visit online catalogue method recognition work especially company real laboratory meet senior project team collaborate national executive number team participate functional boundary roche employee use applause game impressive provide excellent time insight future initiativesour people roche talent strategy pursue recruitment excellence attract well highly skilled motivated people roche offer highly competitive salary student acquire technical scientific skill performancebase reward wide need coming year roche establish variety generous benefit tailor need excellent partnership university expectation location country china spain include pension plan health insurance child shape curriculum switzerland roche care onsite medical facility fitness centre apprenticeship programme achieve strong preventive health screening transportation result local government request workplace employee given train additional student provide qualified opportunity buy roche stock discount graduate apprenticeship programme price country successful replicate south korea finally invest futurelab south san outreach program young people francisco worldclass experio lab way shape future ensure switzerland society help prepare qualified candidate future help generation scientific leadersour people roche ashley magargee roche singapore think impact magnitude unmet need general manager roche affiliate singapore learn step look immediately accustom working fastmove dynamic solution different kind leadership environment experience tanzania took need hereone emphasise work new level leadership development tanzanian counterpart replace programme njiakiswahili pathis decision delegation listen ask keep focus ambiguous environment empower way role model njia partnership roche tanzanian demonstrate structure meeting government notforprofit organisation idea table ensure clear individual responsibility remember team member team roche local particular happy gratifying healthcare leader come rural tanzania develop new skill gain confidence apply leadership skill prevent cervical day return happy show cancer day stay resource passion long sixmonth programme learn medical need compelling tanzanian woman official local healthcare district time likely die disease woman group newfound skill njia develop country convincing case superior acquire inexpensive cryotherapy equipment locally base bukoba western shore lake available resource treat precancerous cervical victoria group focus get treatment lesion group include healthcare woman nearby island test positive practitioner go island perform precancerous cervical cell previous njia team cryotherapy convince save life develop material raise awareness diagnose disease early woman screen treatment screen woman living island different approach leadership roche implement meticulous reflect experience tanzania project plan work tanzania think impact magnitude thing plan unmet need give renew energy lake crossing example powerful storm rock mission roche challenge boat knock electricity island time moreenvironment roche env ironme not roche protect environment legal social obligation integral value material topic cover chapter environmental responsibility contribution un sdgs global company commit mitigate impact environment year proactively seek new sustainable technology furthermore invest innovative technology process achieve environmental goal conduct training programme roche employee focus effort activity environmental total employee participate issue support world hour dedicated training average environmental challenge example climate change approximately hour employee water scarcity pharmaceutical environment commit continuously monitor key address environmental issue performance indicator ensure compliance environmental risk mitigate system standard objective aim achieve prevention successful environmental management key performance indicator system ems establish proactive ems reduce cost increase efficiency enhance roche ecobalance competitiveness measure impact environment ecobalance metric develop swiss federal effectiveness ems review frequently office environment compliant expert team roche site identify risk late guideline metric provide develop mitigation plan dedicated team global view impact earth audit chemical pharmaceutical diagnostic ecosystem manufacture facility plant management local officer conduct frequent check inspection reach ecobalance goal furthermore develop clear define reduction compare process create progress target set aim reduce ecobalance goal initiate action plan goal set area year improvement term decrease people environment business challenge energy consumption air emission volume feasible water consume reduce weight chemical waste lead improvement compare achieve result despite grow production capacity additional building sitesenvironment roche noise pollution emission water primary energy emission air roche ecobalance landfille waste water consumption fiveyear goal natural capital assessment part world water increasingly scarce quality gradual decline restriction use potential cost ecobalance supply increase believe important million pointsemployee develop strategy commit assess water management energy consumption site south san francisco gj ffeemployee natural capital protocol internationally agree framework set business measure monetary value environmental general waste impact dependencie society kgemployee water consumption memployee goal ffe fossil fuel equivalent weight water stress change relate respectively swiss ecofactor ecological scarcity method reduce energy water consumption introduce ecoefficient technologie large proportion energy diagnostic site tucson example operation currently come fossil fuel source establish yearterm agreement oil gas long term local utility provider allow local site goal fully substitute fossil nuclear energy solarpowere renewable energy energy renewable source roche utilise utility provider addition provider wide range practice technique skill validate usage solar power allow roche energy consumption minimum total acquire renewable energy certificate show energy consumption decrease sale reduction emission versus fossil fuel usage grew include decrease energy considerable environmental benefit associate building stationary equipment gas fuel oil initiative include expect reduction waste electricity district heating co emission tucson site year period start energy consumption terajoule vacaville roche site install solar power array solar plant come online total scope generate approximately mwh scope electrical energy avoid carbon dioxide energy scope month venture save consumption gj vacaville approximately usd employee anticipate firstyear saving scope usd business flight share sustainable energy scope energy generate facility eg combustion gas scope purchase energy scope business flight datum collect group gj gigajoule focus measure reduce energy consumption parallel decrease co emission goal nonsustainable sustainableenvironment roche reduce water consumption goal reduce water consumption employee reach year aim continuous improvement long short term approach manage monitor water use locally site use large volume water locate area water scarcity adopt conservation reduction programme accord local need water usage discharge water withdraw million andrea oeri representative found family member board director water consume show strong interest sustainability join safety security health environmental million protection audit thirdparty provider india water discharge treatment plant million organic matter time roche identify discharge waterway global leader action manage water treatment sustainably cdp notforprofit global heavy metal discharge environmental disclosure platform award roche waterway position year water list cdp treatment kg institutional investor asset usd trillion ask company disclose manage risk pose end roche site work worsen water security company water implement programme reduce water usage list receive high rating accordance increase efficiency water usage cdps water scoring methodology reduce emission air water phase greenhouse gas roche want reduce emission source greenhouse gas phase support site require develop action majority greenhouse gas ghg emit plan closely monitor implementation roche group come energy generation effect consist co halogenated hydrocarbon refrigeration plan place able maintain cool plant low level emission air achieve far improvement manufacturing emission air nitrogen oxide site approach work sulphur dioxide increase company reduce halogen halogenate particulate volatile organic compound refrigerant approximately decrease respectively absolute scope scope ghg emission upgrading technology reduce environmental harm cut reduce carbon footprint purchasing energyefficient equipment include hybrid car halogens halogenate refrigerant fire increase sustainable energy supply suppressant ghgs remain monitor employee travel need work atmosphere long period time process total project commit reduction use complete result avoidance tonne halogen compare co emission lead estimate cost save chf million year halogenate hydrocarbon tonne site oceanside successfully instal environmentally friendly freezethaw natural inventory refrigerant system drug substance consume release freeze new unit use energy global inventory include chugai genentech ventana previous one lead estimate annual electrical saving kwh usd utility cost reduction tonne carbon dioxideenvironment roche production pharmaceutical diagnostic product site penzberg germany possible clean water co equivalent emission tonne scope fuel combustion halogenate hydrocarbon scope pre marketbase locationbased total scope marketbase scope business flight energyintensive utility waste change report methodology number different report compress air liquid nitrogen reduce waste safeguard ecosystem aim implement follow waste management chemical waste incinerate landfille strategy activity avoid reduce reuse recycle decrease approximately parallel thermally destroy permit landfilling weight contaminate soil resort inert material remediation activity grenzach germany slag ashe environmentalrelate activity site south san francisco increase approximately discharge wastewater pollutant oneoff activity contribute approximately comply fully relevant regulation include tonne pretreatment requirement elimination rate wastewater treatment plant good idea waste high innovative activity underway site help reach goal idea baseline aim reduce general come organisation example waste employee roche packaging plant kaiseraugst switzerland performance indicator increase approximately syrinx prefille medicine compare reason increase product pack reject prefille syrinx likely awareness campaign aim repacke mean medicine improve reporting category discard chemical waste landfille incinerate waste tonne employee work manufacturer packaging machine find way reintroduce reject syrinx packaging process general waste result annual saving chf million generate significant reduction chemical waste chemical waste generate contaminate soil construction waste prior datum collect separatelyenvironment roche goal safeguard roche genentech site south san francisco collaborate city south san francisco ecosystem protect business environmental protection agency epa reassess specific stream wastewater longterm risk biotechnology production process require collection instead send city wastewater treatment plant mexico china iran host base study perform epa landfill grenzachwyhlen germany show conclude wastewater stream remediation approach young scientist way adversely affect city wastewater treatment share good practice ensure implement operation follow collaboration south san francisco pharmaceuticals environment site able reduce wastewater volume trace pharmaceutical product enter collect lessening co emission environment variety way include transportation offsite treatment change manufacturing process improper disposal unused reduce disposal cost usd medicine natural metabolic process year follow normal patient use share knowledge invest future roche acting concern impact switzerland forefront effort pharmaceutical environment consider environmental protection long history entire lifecycle product broad experience cope environmental pollution issue mabtherarituxan herceptin avastin perjeta lucentis monoclonal antibodie generate th international conference chf billion sale belong biogeochemistry trace element icobte hold define class active pharmaceutical ingredient apis zurich partner eth zurich exempt european medicine evaluation internationally topranke university switzerland agency guideline environmental risk assessment enable phd student postdoctoral scientist low excretion rate judge different country attend sponsor present significant risk sewage work surface technical excursion conference participant water term benign nature learn corporate responsibility innovative constitute environmentally sustainable compound approach remediate landfill chemical product subject rigorous environmental risk assessment young scientist country include india brazil russia chile japan poland pakistanenvironment roche ben fu roche china engagement lead sustainable contribution local community environmental engineer work waterefficient tap showerhead safety health environmental officer new carefully plan landscaping reduce overall water roche diagnostic manufacturing site suzhou near consumption wastewater production shanghai fully operational plant treat reuse purpose produce highquality reagent immunoassay laboratory hospital doctor surgery thank comprehensive approach suzhou contribute improve healthcare patient aim achieve leadership energy china help supply product environ mental design lee platinum certificate asian country high environmental standard green building councilfor administration building need look production ensure safe environment work site colleague feel proud energised neighbourhood general team build new site construction site engineering team beneficial impact patient shape safety course million hour environment positive way enhance work accident need reputation china engagement lead record speakup culture sustainable contribution local community encourage worker point potential safety issue job holistic approach safe achieve high standard sustainability guard health employee include outset manufacturing site programme deal air pollution air quality suzhou design meet high environmental guideline accurate information source standard reduce energy consumption employee check air quality popular instal thick insulation legally require social app wechat air purifier instal solarprotective glazing fix window shading office financial support offer employee decentralise air conditioning switch buy home use air filtration mask efficient lead lighting shut available charge present photovoltaic panel roof produce electricity sunlight cover not family someday child energy need administration building ask job look sky power private home entire year grey father help bluecommunity engagement roche community e ngage not foster innovative philanthropy make longterm sustainable difference community world material topic cover chapter community engagement contribution un sdgs roche common purpose difference live patient family society large global local philanthropic effort local impact matter common focus strengthen community support potential individual organisation longterm sustainable difference strengthen local community form strategic innovative intervention partnership difference aim build strong community strengthen local community environment partner local authority strengthen community operate nongovernmental organisation ngo infrastructure support training respect local custom need educationi important roche responsibility engage employee appropriate global citizen think globally act skillsbased volunteering capacitybuilde locally perspective well exemplified annual project inspire long deeplyembedde roche children walk company site history philanthropy country come donate fund children education health initiative employee approach recognise externally raise money individually company match achieve maximum score fund raise campaign corporate citizenship philanthropy dow jones sustainability indices gold companywide walk standard measure corporate sustainability roche employee participate raise compare industry average chf million total proud additionally philanthropic activity support global children project un sustainable development goal directly support initiativecommunity engagement roche annual roche children walk big employee fundraising project money raise double company children programme support education health social development world picture show roche ambassador visit project malawi example local project benefit meal centre provide psychological support fund raise walk roche counselling basic skill train family member childrens centre mumbai india roche pharma child place child india partner notforprofit organisation recover cancer place st jude india childcare centre facilitate learn new way life hold good social initiative provide holistic care child stead future cancer important effort child live cancer india strengthen community receive proper treatment operate important centre offer family remote area india free place stay child receive treatment roche responsibility global citizen addition help accommodation transport student country work theme foster entrepreneur host international swiss talent forum event provide platform student exchange view learn support potential found sponsor organisation signature believe support potential think tank programme international swiss talent individual initiative right time forum bring motivate young tremendous longterm impact roche encourage people world address current future leader innovator reach potential global issue forum hosted student support scholarship programme empower nation focus theme foster organisation employee volunteer programme entrepreneur science engagement initiative contribute good partnership roche provide example roche long partnership schweizer jugend forscht support practical area collaboration schweizer matter employee complete skill jugend forscht swiss youth science yearold base volunteer assignment foundation foundation focus identify potential provide pro bono consult advice business young scientist inspire innovation roche marketing process improvementscommunity engagement roche partnering difference develop country volunteer programme make sustainable difference entail partner combine capability skill roche community ngos local authority initiative employee ngos build capacity address local need capacitybuilde deliver sustainable output escalate impact roche offer short longterm volunteering programme longterm supporter international shortterm microsecondment programme committee red cross icrc found ngo partner request temporary skillspecific member corporate support group roche consultative support health educationrelate contributed water habitat activity assignment country include pakistan ethiopia liberia uganda burundi eritrea guinea mali roche collaborate variety organisation activity aim ensure people affect armed pro bono skillsshare assignment include conflict access clean water proper sanitation icrc schweizer jugend forscht b education sustainable living environment partnership medicine malaria venture mmv roche pair mmv foundation focus roche contribute icrc project antimalarial drug development mali aim improve access clean water procurement expert foundation want people project build upgrade expand knowledge capacity area water supply system violenceaffecte community academicresearch organisation collaboration personal consumption livestock accelerate drug research agricultural use roche support global organisation believe support potential believe partnership employee ngos local community share knowledge individual initiative right time individual skill end offer skillsbased volunteering programme employee work tremendous longterm impact ngo help improve health education incommunity engagement roche belinda holdsworth roche switzerland teach learn lot interested engineering lead face student eager learn study biochemical engineering university interactive handson practical approach graduation start career process engineer class simulation group activity helped quickly move commission qualification teach fundamental principle supply chain pharmaceutical manufacturing facility management lean manufacturing teamwork join roche operational site manager contract manufacturer locate france present case study dabbawalla hold overall responsibility production activity supply hot lunch worker india lowtech site lead team technical expert incredibly reliable supply chain case study mba thought know inside look new challenge outside student raise question offer insight comfort zone end learn skill consider teach base secondment programme manage roche learn lot corporate donation philanthropy apply programme offer ngo opportunity bring home importance diverse way submit request shortterm skillspecific support thinking solve problem diversity health educationrelate assignment passion lead eu division pharma technical woman professional grassroots initiative roche select microsecondment assignment foster professional development woman organise cooperation b educational partnership week visit look think enthusiasm lecturer operation supply chain topic positive feedback student give namibia university science technology feel inspire study windhoek love africathe natural beauty friendly hopefully future career final day people special energy tourist different teaching student present gift small go work shortterm assignment chair symbolise place africa wrap experience beautiful touching way problemsolve different perspective teach class little strongly recommend volunteer nervous day visit lecturer experience want share skill feel quickly disappear see friendly impact makeintegrity business roche integ r ity bu sine integrity compass guide aspect business behaviour allow fulfil purpose serve patient material topic cover chapter compliance drug efficacy safety patient organisation support supply chain management occupational accident contribution un sdgs w hat compliance general sense mean adhere rule regulation roche go deep compliance mean internalise letter work grey area question foremost spirit law conflict interest improper advantage daily behaviour make impact discrimination harassment point orient mean move formal concept contact line manager recently launch ticking box way business course compliance officer aim translate integrity matter level licence formal guideline business integrate compliance operate society essential effort create positive impact business practice deliver innovative product patient objective build common understanding roche comprehensive compliance management put group code conduct practice system compliance guideline document roche group code conduct come roche dedicated regional local compliance life decision employee day officer affiliate world work chief compliance officer integrity mind poland example local compliance officer translate passion job help colleague understand topic essential compliance roche selection external distributor instance base ethical sustainability criterion integrate business decision poland total employee roche group speakup line available language countrie chief transparency visvis healthcare stakeholder compliance officer receive report relate alleged roche strive mutually beneficial partnership violation code conduct business ethic incident diverse group interact patient advance reporting system incident unfounded access improve quality care patient group investigation substantiate result council ensure patient voice integrate employment contract agreement business partner entire lifecycle medicine patient terminate ground unethical behaviour help understand personal experience andintegrity business roche challenge pose disease provide invaluable insight help improve product development clinical trial programme dialogue physicians essential increase knowledge effectiveness safety current therapy diagnostic prioritise discovery effort accordance industry guideline detail interaction patient organisation public strengthen internal control verification process interaction healthcare professional organisation addition develop guidance affiliate communicate impact healthcare contribution transparent way contribution healthcare stakeholder maintain high marketing standard engage healthcare professional publish online link rule ethical business practice complex difficult employee report promptly appropriate regulatory overview compliance officer roche authority roche employee require belgium tackle challenge create document report drug safety quality issue immediately simple icon common topic complete annual awareness train adverse educational grant promotional event meeting event report healthcare practitioner employee click icon connect internal repository embed human right business key compliance criterion approval roche fully commit support respect workflow require form condense version human right sphere influence create specifically use sale include labour right freedom association representative establish methodology strengthen human right risk assessment relevant healthcare roche safety risk management department supplier service provider way contribution systematically monitor roche medicine increase transparency supply chain base rochecom worldwide patient suffer effect impact assessment operation integrate performance adverse event capture global database finding internal business function htmtabidtab ensure business continuity improve operational resilience datum roche continue solid employee health safety track record key health safety performance indicator help employee stay safe private life campaign increase night visibility prepare home emergency addition establish threat assessment team process roche basel employee security concern workplace home site security officer western european site discuss measure protect logistic network intellectual property accident rate number workrelate accident train adequate security measure working day lose year accident sale marketing organisation ensure quality manufacture mental wellbeing workplace pharmaceutical diagnostic employee engage able cope highly regulate industry addition regulation challenge work perform well fda ema country happy overall reason roche begin requirement stay align implement mandatory workplace mental health risk change regulation require precise communication assessment affiliate emphasis planning execution global scale prevent burnout depression mental issue train highly qualified technician prepare early identification problem site medicine sterile room need special certification screen employee questionnaire hold like aeroplane pilot technician work discussion small group risk certain number hour year test identify indepth discussion manager ensure maintain high standard external expert site offer hour helpline employee anonymously pharma technical operation people audits mental health protection begin roche work quality compliance site site world result good practice world include internal auditor regularly share affiliate inspect manufacturing site ensure adherenceintegrity business roche roche quality standard tough personal datum refer personal datum require law launch potential roche stakeholder include employee project collaboration fda ensure patient ensure adhere strict inspection readiness workstream production regulation embed datum privacy governance system facility equipment quality laboratory business develop training module system material management ongoing employee develop medicine effort include speed corrective preventive tap huge amount patient datum genomic action issue identify information access valuable information long continue uphold roche different manufacturing source trust place protect respect supply product event natural disaster individual privacy process use unforeseeable event use personal datum manufacture site appropriate capacity level contract manufacturing site cover emergency sudden increase demand maintain safety stockpile product raw general manager lead compliance material backup equipment set help need deliver lifesave medicine crucial diagnostic test emergency roche decentralise structure general manager gm safeguard datum personalise healthcare affiliate play important role ultimately datum privacy fundamental human right responsible compliance brazil example gm work protection responsible use personal datum local compliance officer ensure employee anchor roche group code conduct adequately train feel comfortable ask question reflect daily operation response gm regularly review compliance case management meeting european union new comprehensive general datum ask direct report lead protection regulation come effect example show roche interested unethical roche embark companywide project business deal zero tolerance employee cross meet detailed requirement include line noncompliant behaviour clear message documentation assessment process compliance good business develop last partnership foster engagement roche depend network business supplier service provider critical supplier service provider addition partner standard concept ensure compliance quality standard audits conduct supplier sustainability assurance expect adhere high principle visit assurance visit aim build trust add ethic labour environment health safety valuein contrast conventional audits management system mitigate risk see policing act visit ensure business continuity principle second work day world cover detail roche supplier code conduct supplier service provider constructive engagement government require adhere roche want voice hear inform public discussion healthcare aim help advance regulatory framework healthcare ensure sustainable development industry actively engage public discussion membership engage political institution trade industry association efpia medtech europe bio government affair team eu advocate policy roche remain independent political affiliation ensure patient access medicine support association political institution transparent diagnostic tool need goal inform dealing switzerland spend chf million lawmaker policymaker advocacy organisation include payment industry association potential impact policy biomedical chambers commerce financial assistance trade union innovation patient serve roche donation political party cantonal federal level employee involve lobbying effort comply donation political party low doubledigit applicable law regulation eu thousand range swiss franc account funding policyrelate activity approximately total contribution donation document eu transparency register link lobbying expenditure federal initiative approximately usd millionintegrity business roche addition genentech political action committee roche good government committee allow recognition business ethic employee voice encourage election legislator fund solely voluntary mexico employee contribution govern independent board contribute approximately usd federal political candidate confederation industrial chambers united mexican bipartisan manner state award roche mexico ethic values award purpose award highlight good practice accelerate access treatment ethical business company different sector time government healthcare budget assess roche mexico multinational increasingly stretch health technology assessment company pharmaceutical industry receive recognition hta important tool policymaker weigh evidence clinical effectiveness safety costeffectiveness therapy approve regulatory agency eunethta establish create network hta europe include homogenous approach relative effectiveness assessment currently hta national act trust partner example regional body europeeach different fda participate industry representative criteriawhich potentially slow access draft new iteration newly approve medicine prescription drug user fee actthe key source fund medicine review process addition roche collaborating eunethta roche work fda foster great focus pilot hta body authorise develop therapy child cancer relative effectiveness assessment share report hta bodiesavoide duplication europe direct interaction ema effort pilot study focus lung cancer place example scientific advice medicine alecensa pilot help roche learn eus priority medicine prime scheme local regional need hta support accelerate regulatory approval eu transparency process achieve great harmonisation roche actively foster publicprivate exchange register mitigate redundancy speed access information innovative medicine eceuropaeu initiative imi efpia member transparencyregister collaborate regulatory agency drug information association cochair publicconsultation member development regulatory team meet basel focus collaboration displaylobbyist work closely agency world roche regulator hta body payer doidintegrity business roche funke abimbola roche uk compare role compliance orchestra conductor british citizen nigerian descent come listen occasional note key family parent sibling individual aware corrective uncle cousin physician action need decide career law lot convincing age determine compliance crucial protect reputation lawyer opportunity patient need know product meet standard offer achieve social justice profess physician need convinced rely patient life stake regulatory support family attend uk reimbursement authority need assurance university graduating honours law degree transparent act good faith rude awakening not find conduct business uphold high level job discrimination race manage integrity sustained contribution society find position respected inhouse legal measure sale figure team shock return maternity leave london firm work outside work spend great deal time speak expect long hour impossible young people britain difficulty work mother leave london work regional career overcome barrier firm regular work hour share story senior leadersfrom member parliament chief executivesand suggest way embed compliance daily work involved level playing field join roche compliance mean advance equality proud son respect spirit letter law recognise school leadership govern industry different implication support champion equality people diverse job research clinical development sale proactive communication stun humble news make right decision relevant compliance award queen honour situation important appoint member excellent order british empire mbe equality work compare role compliance help young people reach potential orchestra conductor time people open new door positively impact sync play harmoniously job peoplecorporate governance roche cor porate gove r nance principle roche corporate governance principle focus corporate governance requirement particular business activity sustainable value creation applicable law swiss stock exchange innovation prescribe management culture swiss exchange directive swiss code conforming recognise standard good corporate good practice corporate governance promulgate governance policy transparent communication swiss business federation economiesuisse principle build basis successful company internal governance framework particularly implementation roche commitment serve article incorporation bylaw embody stakeholder principle need ensure company business manage supervise manner strong board director represent consistent good corporate governance include interest shareholder stakeholder necessary check balance highly skilled manager act integrity extremely important print annual report contain select link roche website wwwrochecom reader th consecutive year roche provide snapshot recognise dow jones sustainability indices company report date direct group leader sustainability source consult time pharmaceutical biotechnology life science uptodate information corporate governance industry sustainability core business roche annual report cover single practice award reflect commitment financial year end december website run business way ethical responsible contain information permanent nature create longterm value stakeholder late roche news company article incorporation bylaw curricula vitae corporate governance report set member board director corporate structure process rule roche take executive committee publish website basis wellfunctione corporate governance roche complie relevant detail refer follow report annual general meeting annual general meeting board director board director board committee presidium nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceutical diagnostic counsel enlarge corporate executive committee enlarge corporate gred pre partnering communication executive committee chugai rochecomgovernancecorporate governance roche board director th annual general meeting agm march forthcome agm roche holding ltd march shareholders board director nominate chairman reelect dr christoph franz chairman remain member board director board director reelection furthermore agm reelect andr hoffmann board director nominate prof sir john bell julie brown paul bulcke prof dr dr christoph franz andr hoffmann richard p lifton dr andreas oeri bernard poussot prof dr richard p lifton bernard poussot dr severin schwan dr claudia suessmuth dyckerhoff peter r voser reelection member peter r voser elect anita hauser new remuneration committee agm member board director term year provide article incorporation previous year board director prof dr pius baschera stand reelection nominate bdo ag independent proxy period conclusion addition agm elect dr christoph franz ordinary annual general meeting shareholders andr hoffmann prof dr richard p lifton bernard election agm poussot peter r voser member remuneration committee organising meeting immediately follow agm board director determine structure composition remain committee show page board director corporate executive committee composition year birth elect board director dr christoph franz c e chairman andr hoffmann representative c e vicechairman shareholder group pool voting right dr andreas oeri representative e shareholder group pool voting right prof sir john bell b e julie brown b e paul bulcke b e anita hauser e prof dr richard p lifton c e bernard poussot c e dr severin schwan f dr claudia suessmuth dyckerhoff b e peter r voser c e secretary dr gottlieb keller board director honorary chairman dr fritz gerber board director corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson corporate executive committee membership corporate executive committee remain unchanged information member corporate executive committee enlarge corporate executive committee list page board director corporate executive committee composition year birth position corporate executive dr severin schwan ceo roche group committee daniel oday ceo roche pharmaceutical roland diggelmann ceo roche diagnostic dr alan hippe chief financial officer cristina wilbur head group human resources dr gottlieb keller general counsel enlarge corporate osamu nagayama chairman ceo chugai executive committee dr michael varney head genentech research early development gre prof dr john c reed head roche pharma research early development pre dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris ian starkey mark baillache business year chief compliance officer dr urs jaisli corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceutical diagnostic counsel enlarge corporate executive committee enlarge corporate gred pre partnering communication executive committee chugaicorporate governance roche group structure shareholder roche operate business organise shareholder relate party page division pharmaceutical diagnostic note financial statement roche pharmaceutical division comprise business hold ltd significant shareholder exchange segment roche pharmaceutical chugai addition significant shareholder publish regulation genentech segment relevant webpage disclosure office sixexchange integrate roche pharmaceutical diagnostic exchange regulation regulationcom division consist follow business area significant centralise point care solution andr hoffmann vicechairman board shareholder name professional diagnostic molecular director chairman remuneration diagnostic tissue diagnostic diabete care committee dr andreas oeri member board director chairman board business activity carry group corporate governance sustainability committee subsidiary associate company detail serve respective capacity board information roche holding ltd significant committee representative shareholder subsidiary associate company include group pool voting right receive company list information domicile share remuneration set forth remuneration report capital equity interest list finance finance report note report note roche group consolidated roche group consolidate financial statement financial statement list subsidiary relate party exception associate dr jrg duschmal work postdoc roche relationship exist shareholder major shareholder list finance report pool voting right note roche group consolidate financial statement equity attributable roche crossshareholding roche pharmaceutical incl genentech pharmaceutical chugai centralised point care solution molecular diagnostic diagnostic tissue diagnostic diabetes care composition capital structure information roche capital structure provide nes holder describe article finance report note financial statement incorporation roche hold ltd roche holding ltd additional detail contain article incorporation roche information debt instrument hold ltd issue outstanding bond provide finance report note roche group movement recognise amount consolidated financial statement debt financial year detailed finance report note financial statement roche information employee stock option provide holding ltd finance report note roche group consolidate financial statement equity company share capital chf compensation plan include detailed divide fully pay bearer share information stocksettle stock appreciation nominal value chf restriction right ssar plan roche restrict stock unit exercise voting right share rsu plan roche performance share psp plan deposit share vote restriction roche connect roche option plan authorise conditional capital roche issue option apart employee stock option describe finance report addition nonvoting equity security note roche group consolidated financial ne issue bearer form statement equity compensation plan form share capital confer voting option issue connection debt instrument right ne confer right share participate available earning option award employee liquidation proceed follow repayment share debt instrument issue capital roche nes right pertain thereto effect roche share capital include provision protect interest rochecomarticleofincorporation rochecomboardofdirector rochecomexecutivecommittee rochecomarticleofincorporation rochecomannualgeneralmeeting rochecomarticleofincorporation rochecomcommittee rochecomarticleofincorporationcorporate governance roche board director corporate executive committee information member board director year preceede current reporting period member corporate executive lack exist business connection committee list page member group subsidiary independent roches board director age limit restriction board director independence definition base term office curriculum vitae current definition swiss code good practice member year corporate governance economiesuisse body information include information complement specific precede criterion year election board member rochecomboardofdirector additional position membership activity available continuously update internet principle governance principle delegation competence reservation power management rule pursuant article para point vegv group company executive body number permit activity board company include economic environmental director corporate executive committee social topic principle internal member outline article organisation board director division incorporation roche holding ltd authority responsibility board management remit board committee annual general meeting elect information control mechanism available member board director chairman board dealing corporate management board director member govern bylaw remuneration committee annual basis election nominee vote separately board director roche holding ltd article incorporation roche organise ensure group conduct hold ltd minute th annual business responsibly focus longterm general meeting roche holding ltd hold value creation end roche board march delegate certain responsibility committee composition chairperson december exception dr severin schwan describe committee member board director office authority responsibility define detail end member roche corporate bylaw board director executive committee serve executive capacity group subsidiary financial committee chair independent director board director board director board committee presidium nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee accord bylaw board director auditor finding present audit board meeting convene chairman committee board detail risk present request member roche management include risk factor risk board meet year assess chairman management policy risk management performance meeting attend website financial risk management specifically chairman chair vicechairman describe finance report system internal control financial report management information system mis page finance report board director regularly inform internal audit important issue sale performance etc group audit report general counsel board access electronic information platform direct access give regular briefing audit provide timely information board committee corporate governance director board committee sustainability committee ongoing activity system control set forth audit report chief audit risk advisory executive attend audit committee partly board director establish system corporate governance sustainability control continuously monitor committee meeting external auditor audit committee corporate governance group audit independent appraisal function sustainability committee board evaluate review group activity director consist follow element service management annual audit plan report operate financial risk risk yearly define focus area eg market access management system party management validate senior management roche group establish risk management present audit committee roche process cover entire company system group commit maintain high standard place identify manage type risk internal control worldwide potentially affect business include economic operation management responsible assess environmental social impact risk business risk aspect operation opportunity contain stakeholder input implement effective efficient process board director high governance control whilst ensure compliance internal body involve roche risk management policy set external rule regulation approach accompany responsibility conduct operational audits group audit pharmaceutical diagnostic division determine management response risk global function conduct formal risk assessment surround business process system process year develop risk evaluates appropriateness completeness plan material risk efficiency process control action plan monitor deviation review regular implement necessary change enhancement performance dialogue consolidate group risk develop businessauditee report include target risk profile discuss track completion corporate executive committee approve statutory auditor group business plan material chief compliance officer compliance officer risk review board yearly basis subsidiary effectiveness risk management process safety health environmental protection monitor group risk advisory team department overall process regularly review external corporate sustainability committee rochecomriskmanagement additional information provide finance report note roche group consolidate financial statement risk management rochecomenvironment rochecomsustainabilitycorporate governance roche science ethic advisory group seag board director meet meeting issue relate genetic genetic engineering generally hour length include fullday meeting addition day visit member corporate executive committee major subsidiary invite attend meeting board board committee meet follow director report person agenda presidium board directorsnomination item concern situation warrant committee meeting approx hour member enlarge corporate executive remuneration committee meeting approx committee invite attend board hour committee invite chairman board audit committee meeting approx hour corporate executive committee member deliver report committee meeting elect corporate governance sustainability commission independent expert report committee meeting approx hour service consultant board director regularly conduct year blackout period impose assessment selfassessmentassessment party senior employee prohibit electronical survey personal interview trade company stock follow blackout performance selfassessment board period effect director addition selfassessment december february audit committee conduct april april june july members corporate executive committee october october maximum ordinary notice period month blackout period change chairman changeofcontrol clause board director circumstance warrant employment contract management contract fall scope subsection annex directive information relate corporate governance rochecomethicalconflict remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activity dr andreas oeri chairman corporate governance sustainability committee sheaudit india photo gak board board committee attendance corporate presidium governance nomination remuneration audit sustainability board committee committee committee committee number meetings ch franz hoffmann j bell j brown p bulcke hauser march rp lifton b poussot schwan oeri c suessmuth dyckerhoff p r voser retired board member retire march p baschera member committee invite guest board committee meetingscorporate governance roche remuneration shareholding loan rule aol detail remuneration shareholding loan content method determine content board cec compensation shareholding programme rule principle basic principle element compensation applicable performance shareholding programme serve related pay member board director corporate rule principle executive committee description allocation equity security authority procedure determine convertible right option set forth separate remuneration report additional payment page finance report note member executive roche group consolidated financial committee appoint statement equity attributable roche shareholder vote pay general relate party page list meeting shareholder note financial statement roche holding rule loan credit facilities ltd board executive shareholding postemployment benefit rule vote pay follow rule remuneration shareholding agm loan board director board corporate executive committee cec set forth article incorporation aoi participatory right shareholder participatory right shareholder define article incorporation roche article incorporation roche shareholder represent share nominal value share issue bearer restriction chf million request placement admission annual general meeting item agenda annual general meeting exception share deposit later day specify period date meeting date meeting admittance card issue shareholder provide article rule issue instruction incorporation shareholder elect independent proxy rule electronic represent party annual general participation agm lay meeting correspond invitation agm regulate article incorporation article incorporation contain restriction exercise voting right quorum requirement stipulate conformity swiss code obligation rochecomarticleofincorporation change control defensive measure article incorporation contain provision terminate event acquisition mandatory bid rule swiss law apply vest period restriction preexist award remove option changeofcontrol clause exercise immediately component remuneration base roche ne relationship statutory auditor annual general meeting roche holding ltd report statutory auditor consolidated march shareholder vote appoint financial statement financial statement kpmg ag kpmg statutory auditor base find page respectively exist legal requirement swiss code year finance report obligation article concern maximum term office seven year auditor charge kpmg receive follow remuneration ian starkey auditorincharge business year service statutory auditor roche holding ltd replace mark baillache start auditor roche company business year information long include chugai auditor auditorincharge serve capacity provide statutory auditor participate audit committee meeting millions chf prepare write oral report result audit service audits audit committee oversee auditrelated service assess auditor make recommendation assurance board information authority non statutory audits responsibility audit committee article tax service bylaw statutory auditor participate service meeting audit committee total rochecomarticleofincorporationcorporate governance roche statutory auditor elect year service include advice relate process annual general meeting improvement regulation training auditing service provide legally require company formal policy governing engagement statutory auditor nonaudit auditrelated service include assurance accounting service policy prohibit certain service service provide auditor provide permit certain service necessarily provide statutory auditor limit agree audit committee service legal requirement potential nonaudit service engagement review include attestation service comfort letter policy authority proceed consent consultation give tax service include service respect compliance tax return tax advice service relate audit tax relationship independent proxy recent year bdo ag serve independent rule issue instruction proxy annual general meeting independent proxy rule electronic march shareholder elect bdo ag participation agm lay independent proxy period correspond invitation agm conclusion ordinary annual general regulate article incorporation meeting shareholder bdo ag pay service annual general meeting accord expenditure totalling chf chf information policy provide article incorporation relevant information document include corporate notice publish swiss official medium release investor update presentation gazette commerce daily newspaper analyst investor conference available designate board director basler zeitung internet publication available finanz und wirtschaft lagefi le temps neue rochecompublication order zrcher zeitung email fax baselwarehouseservicesrochecom fax roche report halfyear fullyear result business report publish print andor online contact address investor relation format medium event addition detail f hoffmannla roche ltd investor relation firstquarter month sale figure group finance basel switzerland publish year april october tel current list publication date available fax english german internet additional information include detail specific contact person available internet rochecomarticleofincorporation rochecommedia rochecominvestor rochecominvestorscontactscorporate governance roche chief compliance officer compliance officer network chief compliance officer compliance addition roche establish business ethic officer network commit ensure incident report beir system enable roche group code conduct consistently chief compliance officer capture track comply roche group monitor allege violation initial report serve contact person shareholder employee local compliance officer resolution customer supplier general public issue relate implementation compliance business ethic incident record system code employee party group internal investigation department aware violation roche group code conduct regionallocal management receive specific bring attention manager concrete information allege violation supervisor local compliance officer report roche group code conduct certain pre chief compliance officer dr urs jaisli define category corporate governance direct phone number email sustainability committee audit committee ursjaislirochecom disclosure treat board director inform substantial confidentially addition end violation management corrective action employee anonymously report irregularity complaint mother tongue speakup chief compliance officer report general line start december new compliance counsel submit regular report tool group level socalle roche group code corporate governance sustainability committee conduct help advice line introduce need audit committee board strive provide guidance case question director uncertaintie interpretation roche group code conduct reference document furthermore serve platform idea suggestion concern document nonapplicabilitynegative disclosure expressly note information contain provide swiss exchange corporate mention nonapplicable governance directive commentary thereto omission construe negative declaration rochecomcodeofconduct rochecomriskmanagementremuneration report roche mune ration por material topic cover chapter executive remuneration principle roche success depend substantially global company like roche marketcompetitive expertise motivation performance remuneration play key role employee conviction form basis performancebase transparent compensation compensation policy structure ensure compensation package competitive structure individual roche aim remunerate employee fairly component regularly benchmarke swiss transparently line market condition european international criterion remuneration enable participate appropriately guideline underlying principle company success pursue goal provide subject regular outside comparison competitive performancebased resultsoriente compensation compensation policy factor safeguard roche future success key strive balanced mix fix variable element corporate culture offer employee compensation component gear employee condition good possible position management responsibility contribution share corporate goal improve healthcare patient include sound value firstly variable component intend create system base integrity courage passion additional financial incentive achieve corporate time decentralise management goal innovation consistently high approach play major role wide scope compensation level increase value company individual decisionmake respectful interaction policy create stakeholder group secondly order openness diversity wideranging training rochecomreward allow employee manager participate development opportunity attractive working company business success adequate compensation environment unidimensional diminishment sound value system measure key objective incentivise question remuneration fall far short rochecomlive annual bonus payment longterm sharebase ourvalue programme roche commit fair performancebase resultsoriente compensation policy link employee interest stakeholder groupsremuneration report roche remuneration decision process approval framework overview term longterm orient performance year remuneration committee roche share plan psp award decide annually board director decide remuneration board board director act recommendation member member group corporate remuneration committee executive committee remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman c committee cec incl ceo roche group base payremuneration bonus c remuneration committee stocksettle stock appreciation right annual general performance share plan board director meeting recommendation remuneration committee decision pension c remuneration committee remuneration committee track market datum total aggregate amount base salary lead global pharmaceutical decision submit general company major swiss company meet approval implement ordinance report finding board external excessive compensation list corporation consult firm pricewaterhousecooper pwc verordnung gegen bermssige vergtungen bei assist remuneration committee roche brsenkotierten aktiengesellschaften vegv perform market comparison advise general meeting shall vote annually bind information remuneration committee remit effect approval remuneration power procedure make remuneration board director resolve board decision find bylaw roche director corporate executive committee board director article detail incorporation outline section principle govern specific remuneration component peer set abbott laboratories abbvie amgen astella astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compare abb credit suisse lafargeholcim nestl sonova straumann swis ubs zurich insurance rochecomarticleofincorporation rochecomarticleofincorporation andr hoffmann chairman remuneration committee peer set abbott laboratories abbvie abb amgen credit suisse astellas lafargeholcim astrazeneca nestl roche bayer sonova bristolmyers squibb straumann eli lilly swiss glaxosmithkline ubs johnson johnson zurich insurance merck co peer set novartis pfizer sanofi takeda market comparison company salary assessment pharma peer set major swiss companiesremuneration report roche procedure submit total board retrospective approval executive remuneration shareholder approval total aggregate bonus amount corporate annual general meeting executive committee chairman board year annual general meeting agm director financial year end shareholder approve total remuneration submit retrospectively ordinary agm board director corporate executive separate bind approval committee decide board director remuneration committee board director prospective approval respectively board executive aggregate remuneration submit prospectively agm separate accord approval agm roche bind approval period commit obtain separate bind ordinary agms shareholder approval total remuneration pay board director corporate executive committee follow approval total remuneration annual general financial year financial year meet retrospective chairman bod c c bonus financial year total bonus corporate executive committee cec include ceo roche group cec bonus bonus financial year total prospective board director bod include c bod base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec include cec ceo roche group base pay aggregate total remuneration agm agm ssar psp base pay indirect benefit stocksettle stock appreciation right ssar performance share plan psp indirect benefit agm agm agm remuneration component overview remuneration element lti remuneration component intend remuneration member board sustainably homogenously longterm orient director corporate executive committee align management interest shareholder compose follow element concrete holder nonvoting equity security composition chart composition participate manager additional incentive remuneration board director achieve value growth form longterm total corporate executive committee shareholder return fix base salary complement annual variable bonus shortterm incentive sti perennial variable remuneration element ssar psp longterm incentive lti remuneration component link employee performance company financial performance commercial success align interest roche employee shareholder composition remuneration board director corporate executive committee annual remuneration element description c bod ceo roche group cec base pay monthly payment q uarterly remuneration payment bonus annual payment year year cash block share block share pension etc perennial remuneration element stocksettle stock appreciation right ssar performance share year plan psp block non vote equity security sharesremuneration report roche variable sti base salary bonus indirect benefit employer contribution lti pension insurance contribution stocksettle stock roche connect roche appreciation right tax consulting service performance share plan remuneration expense allowance component children school cost foreign tax obligation ahvivalv fix base pay fix achievement measurable qualitative base pay cash payment determine individual functional performance objective position base salary market datum lead competitive reason roche disclose global pharmaceutical company footnote individual performance objective member major swiss company footnote corporate executive committee chairman reflect individual ability experience performance time pay adjustment likewise december end reporting year link individual performance account january follow report year remuneration prevail market condition company committee decide bonus amount overall financial situation payable chairman board members corporate executive committee respect remuneration committee make review current reporting year base performance final decision individual base pay pay aforementioned objective chairman board director member time remuneration committee decide corporate executive committee form bonus award ie cash payment remuneration member board andor longterm block nonvoting equity security andor block share bonus variable bonus annually award individual stocksettle stock appreciation right contribution value creation business year ssar variable mean incentive strive outstanding ssar entitle holder benefit financially result create new business opportunity increase value roche nonvoting equity bonus amount link group divisional security grant date exercise date core profit sale growth constant exchange rate ssar grant vest operate profit capital charge opac base year exercise seven year core operating profit core earning share grant date unexercised ssar lapse nonvoting equity security ne growth constant compensation fair value ssar exchange rate product development pipeline diversity calculate grant date trinomial employee manager environmental goal model american option detail ssar corporate executive committee restrict stock unit rsus allocate individually remuneration restrict stock unit rsus committee discretion addition remuneration component corporate employee receive ssar executive committee replace award correspond psp performance share plan psp variable longterm incentive programme corporate psp establish period executive committee comprise psp award year base threeyear comparison ssar approximately total shareholder return tsr peer structure lti simplify comparison company footnote competitor company longterm performance mirror share price respective year psp consist tsr shall reflect strongly overlap performance cycle new cycle corporate executive committee remuneration start begin year cycle finishing end year indirect benefit overlap performance cycle psp show ceo roche group psp psp chairman respectively member psp closed december corporate executive committee additionally receive indirect benefit payment pension fund mgb stiftung der f hoffmannla roche ag fr plan key performance metric award mitarbeitergewinnbeteiligung als ergn zung der tsr calculate threemonth move beruflichen vorsorge ie employee profitshare average rate start end foundation supplement occupational pension performance cycle payment psp benefit insurance roche connect payment determine board director annual foreign tax obligation tax consulting service basis act recommendation annual expense allowance show remuneration committee individual member corporate executive committee receive payment psp award remuneration component schooling cost child reserve corporate executive committee enlarge corporate executive committee whilst previous year member senior psp historical performance management participate psp award originally target nes longterm incentive programme previous psp participant comprise ssar rsus approximately remuneration report roche weighting fixedvariable remuneration component target percentage total remuneration chairman board director corporate executive committee include ceo roche group fix variable ratio variable remuneration component relative fix base pay corporate executive committee ratio variable remuneration component bonus ssar psp relative value fix base pay sti lti criterion bonus ssar psp individual target value minimum maximum performance criterion group objective group divisional value development value development business performance individual determined performance determine performance objective consider core profit sale plus value adjustment plus value adjustment growth constant exchange rate dividend ne dividend nesbearer operating profit capital charge opac grant share grant base core operating profit core earning group performance tsr share nonvoting equity security relation tsr performance ne growth constant exchange rate peer set tsr definition product development pipeline diversity employee manager environmental goal split group objective na b individual objective na na applicable assess consideration performance competitor macroeconomic development base annual base pay measure january year cycle detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding remuneration board director resolution approval remuneration member remuneration chairman board board director director member board director member board director decide remuneration committee receive remuneration additional compensation discretion take account market comparison form quarterly fix cash payment show remuneration member board remuneration form cash payment director table board annually track market datum director activity roche pay legally require employer pay lead global pharmaceutical contribution total chf swiss social company footnote major swiss security programme provide retirement disability company footnote assist unemployment benefit ahvivalv consultancy pwc member board director legally require contribution separately state previous year board chairman board director director separately submit total aggregate bonus chairman board director basic remuneration board director general meet financial year exclude chairman remain unchanged retrospectively bind approval maximum amount total aggregate exception chairman board remuneration board director period director bonus form block share ordinary general meeting dr severin schwan executive member ordinary general meeting table board member board director previous year general meeting award share nonvoting equity security prospectively bind approval ssar loan credit grant member board director capacity member chugai international council cic chugai pharmaceutical co ltd andr hoffmann receive honoraria amount total usd chf advisory service genentech scientific review board prof dr richard p lifton receive honoraria amount total usd chf list member position committee membership chairmanship detiduaremuneration report roche remuneration member board director chf additional remuneration additional special total basic remuneration committee memberschair remuneration remuneration ch franz chairman total remuneration pay chairman board director hoffmann vicechairman j bell j brown p bulcke hauser march rp lifton oeri b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff pr voser p baschera retire march total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration pay period january march additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration detidua remuneration member board director chf additional remuneration additional special total basic remuneration committee memberschair remuneration remuneration ch franz chairman total remuneration pay chairman board director hoffmann vicechairman p baschera j bell j brown march p bulcke rp lifton oeri b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff march pr voser julius retire march b weder di mauro retire march total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration pay period january march additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration total remuneration pay chairman form bearer share block year payable board director april shareholder bind vote chairman dr christoph franz receive total ordinary annual general meeting agm remuneration show remuneration committee bonus proposal adopt chairman total remuneration contain late respect financial year total remuneration board director detiduaremuneration report roche total remuneration pay board board remuneration subject approval director annual general meeting calendar year member board director receive remuneration include submission chairman total aggregate bonus employer contribution social bonus bind vote annual general security beneficial part totalling chf meeting chf exclude additional employer remuneration chairman board contribution pay ahvivalv totalling director include bonus award chf chf chf form share block year show form remuneration table section total remuneration pay chairman board director board remuneration pay member director submit remuneration committee board director bonus proposal adopt late chairman member board director dr franz b board dr christoph franz respect humer receive fee amount total financial year payable april exclude legally usd chf serve member require employer contribution ahvivalv board director chugai international shareholder bind vote ordinary council cic chugai pharmaceutical co ltd annual general meeting member board director william burns receive honoraria amount total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration pay detidua total remuneration pay chairman board director chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowance total form share block year calculation number share base share price date transfer april respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively nclude employer contribution social security beneficial part gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit additionally employer contribution ahvivalv chf chf pay form remuneration detidua retrospective approval chairmans total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base share price date transfer april april april respectively approval agm agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm agm respectively submission board total aggregate dr severin schwans remuneration show future remuneration bind shareholder vote receive function ceo roche group board director propose member corporate executive committee ordinary agm approve board remuneration totalling include corporate chf exclude legally executive committee total remuneration require employer contribution ahvivalv exclude bonus period end ordinary agm prospective approval board total aggregate future remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report remuneration comparison ordinary agm ordinary shareholder approve remuneration agm actual remuneration amount member board director chf exclude legally require employer ordinary agm approve board remuneration contribution ahvivalv exclude bonus total chf exclude legally require employer contribution ahviv alv exclude bonus period end ordinary agmremuneration report roche prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approve agm actual total remuneration pay calculation end period approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding relate party note director andr hoffmann dr andreas oeri financial statement roche holding ltd member founder family closely significant shareholder addition associate belong contractually bind december december shareholder group pool voting right respectively member board director end group hold share person closely associate hold roche issue share detailed information share nonvoting equity security nes group find finance report note american depositary receipt adrs show roche group consolidated financial statement table security holding security holding share ne december december non vote nonvoting equity close relative equity close relative security security security security share ne holding share ne holding number number numbertype number number number numbertype number board director ch franz hoffmann j bell j brown p bulcke hauser ne na na na na rp lifton adr oeri b poussot schwan security holding security holding corporate executive committee corporate executive committee c suessmuth dyckerhoff pr voser retired board member retire march p baschera na na na na total ne adr na applicable share hold shareholder group pool voting right list jointly hold close relative roche adr american depositary receipt list otcqx wwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin trade usd adr represent underlie ne remuneration corporate executive committee resolution approval remuneration committee board remuneration member corporate director outline remuneration executive committee decide decision process approval framework remuneration committee discretion take account market comparison member corporate executive committee receive remuneration work previous year board show remuneration director separately submit total aggregate ceo roche group dr severin schwan bonus corporate executive committee explain detail general meeting financial year retrospectively bind approval high total remuneration pay dr severin schwan member corporate maximum amount total aggregate executive committee remuneration corporate executive committee dr severin schwan executive member board period ordinary general meeting director receive remuneration primary ordinary general meeting function ceo roche group reflect table previous year general high total remuneration pay member meeting prospectively bind approval corporate executive committee include total pay corporate remuneration member executive committee total remuneration corporate executive committee pay member corporate executive general provision assign authority decision committee corporate executive committee remuneration toremuneration report roche high total remuneration pay dr severin schwan member corporate executive committee chf base salary ssar pension fundsmgb insurance roche connect bonus subject approval total aggregate bonus corporate executive committee annual general meeting block nonvoting equity securitiesshare psp payment expense allowancefor tax consulting service total calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value include employer contribution social security beneficial part detailed calculation remuneration annual report number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit share block year calculation number share base share price date transfer april approval agm target number nonvoting equity security psp nonvoting equity security multiply nonvoting equity security price average month october december prior start performance cycle chf nonvoting equity security target number bearer share psp bearer share multiply bearer share price average month october december prior start performance cycle chf bearer share include annual expense allowance chf payment tax consulting service chf chf additionally employer contribution ahvivalv chf chf pay form remuneration base pay member corporate executive committee base pay chf r diggelmann hippe g keller oday c wilbur total base pay include prorate remuneration period march december member corporate executive committee detidua detidua bonuse member corporate dr severin schwan members executive committee corporate executive committee receive bonus remuneration committee board director cash payment april determine corporate executive committee dr severin schwan receive bonus member bonuse base performance form roche share block year agree objective total aggregate bonus payment april bonus bring forward bind vote annual general meeting bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting r diggelmann hippe g keller oday c wilbur total prorate remuneration period march december stocksettle stock appreciation right fair value ssar calculate grant ssar member corporate date trinomial model american options executive committee trinomial model effective method ssar show ssar table valuation american option consider entitle holder benefit financially possibility exercise option time prior increase value roche nonvoting equity maturity call american option compare security ne grant date european option allow exercise exercise date strike price ssar maturity date term multiyear plan closing price roche ne grant date ssar vest year number ssar strike price expiry date grant date vest ssar exercise grant value ssar show convert ne seven year grant ssar table number ssar date unexercised ssar lapse compensation calculate time issue enter value table page information trinomial model american option refer boyle phelim p lattice framework option price state variable journal financial quantitative analysis volume issue mar rochecomtrinomialmodelpdf strike price table ssar detiduaremuneration report roche stocksettle stock appreciation right ssar chf ssar ssar r diggelmann hippe g keller oday c wilbur total performance share plan psp roche security perform well average member corporate executive committee peer set board director elect increase psp award remuneration component nes bearer shares award maximum award reserve corporate executive committee double originallevel reserve target number enlarge corporate executive committee nes bearer share accord psp plan plus previous year member senior management value adjustment equivalent participate performance share plan sum dividend pay vest period attributable number nonvoting equity psp consist overlap threeyear security bearer share individual performance cycle new cycle beginning award grant require roche year cycle progress security perform well psp psp psp peer set event investment psp close december roche security underperform average return target bearer share award deliver peer company few ne psp december bearer share award targeted ne award psp december target nes nes reserve plan award historical psp performance member corporate executive committee show table board director decide actual level provision plan number ne bearer share cash equivalent awards nonvoting equity security nes bearer share psp cycle close reserve participant cycle financial year respectively aim number security actually award depend psp provide incentive participant extent investment roche achieve longterm value growth security share ne outperform average return investment security issue set end psp cycle base peer company comparison base threemonth average distribute dividend security market price dividend yield ie totalling chf billion chf billion total shareholder return tsr reduce effect chf billion chf billion shortterm market fluctuation security price accord term plan participant average month october december receive originally target bearer share prior start performance cycle month october december end cycle footnote detidua restrict stock unit member roche connect voluntary stock purchase plan corporate executive committee offer employee opportunity buy roche rsus remuneration component nonvoting equity security nes corporate executive committee replace equal annual salary discount award correspond psp ne purchase plan subject variable longterm incentive programme hold period year switzerland corporate executive committee comprise psp award ssar approximately addition member corporate executive committee receive annual expense allowance indirect benefit member member payment foreign tax obligation corporate executive committee tax consulting service show table employer contribution social security scheme pension plan groupwide employee stock purchase plan roche connect respect member corporate executive committee show indirect benefit employer contribution table employer contribution show table detidua performance share plan psp fair value grant fair value grant nonvoting bearer share equity security bearer share ne ne price price average average month fair value month october target number october target number december nonvoting december nonvoting prior fair value equity security prior start equity security target number start target number ne psp performance ne psp bearer share performance cycle bearer share cycle psp psp psp psp number value chf value chf number value chf value chf r diggelmann hippe ga keller oday c wilbur total calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value calculation value nonvoting equity security consideration reduction value block period year reduce market value remuneration report roche detidua detidua indirect benefit employer contribution chf pension payment pension payment fund annual taxtax fund annual taxtax mgb expense roche consulting mgb expense roche consulting insurance allowance connect service insurance allowance connect service r diggelmann hippe g keller oday c wilbur total include employer contribution social security beneficial part mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit remuneration loan member remuneration include bonus employer corporate executive committee contribution social security beneficial part base contractual obligation roche totalling chf chf pay individual member corporate exclude additional employer contribution executive committee children schooling pay ahvivalv totalling chf cost totalling chf chf chf form remuneration aforementione additional payment include total remuneration member corporate additional remuneration executive committee mention payment pay current member corporate executive committee loan credit grant member corporate executive committee executive remuneration subject approval annual general meeting maximum regular period notice member corporate executive committee month submission executive total aggregate changeofcontrol clause bonus bind vote annual employment contract general meeting board director propose award member remuneration member corporate executive committee bonus corporate executive committee dr severin schwan form roche share pension totalling chf block year member chf pay corporate corporate executive committee cash executive committee member payment totalling chf respect financial year chf total remuneration pay member exclude legally require employer contribution corporate executive committee ahvivalv submit propose total calendar year member ordinary annual general meeting corporate executive committee receive agm binding vote detidua detidua detidua retrospective approval member executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv submission executive total future aggregate incentive ssar calculate grant value remuneration bind shareholder vote consider reduction value board director propose block period applicable psp calculate ordinary agm approve remuneration time reservation nonvoting equity security corporate executive committee totalling bearer share take account maximal chf exclude legally require potential double consider reduction employer contribution ahvivalv value block period contribution exclude bonus period end pension benefit exclude legally require employer ordinary agm contribution ahvivalv contribution expense payment foreign tax obligation executive total future aggregate tax consulting service roche connect remuneration compose base pay longterm prospective approval member executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonusesremuneration report roche reconciliation report remuneration exclude bonus period end shareholder prospectively approve ordinary agm remuneration member corporate executive committee comparison ordinary agm ordinary agm approve remuneration ordinary agm remuneration amount corporate executive committee totalling chf exclude legally require employer chf exclude legally require contribution ahvivalv exclude bonus employer contribution ahvivalv psp assumption maximum value prospectively approve total remuneration member executive committee comparison actual total remuneration effect chf period period period agm agm agm agm agm agm maximum total remuneration prospectively approve agm total remuneration calculate end calculation end corresponding agmagm period period agm agm actual total remuneration realise corresponding agmagm period base calculation end calculation end actual calculate restrospectively end psp end end correspond psp cycle cycle psp cycle approve limit calculation end period yes yes additional pay new member corporate executive committee approval agm approved total exclude legally require employer contribution ahvivalv exclude bonus include assumption maximum possible award bearer sharesnonvote equity security correspond psp cycle award bearer share psp cycle originally include calculation maximum possible award total remuneration period agm agm reduce chf clawback accord regulation psp programme addition applicable statutory provision originally target award ne share roche longterm incentive plan include option shall lapse compensation notice partially reclaim distribute compensation termination employment give reason result special circumstance clawback redundancy disability retirement employee voluntarily serve notice guideline security holding termination employment ssar board director decide ceo rsus unvested date roche group cec member acquire termination employment lapse immediately share andor ne equivalent annual base compensation salary ceo roche group equivalent annual base salarie annual base salary termination employment result respectively end retain misconduct ssar rsus grant holding long serve cec outstanding vest unvested shall lapse exception cristina wilbur join immediately compensation accord corporate executive committee ssar plan rule misconduct fulfil requirement end participant include inter alia members corporate executive committee activity lead disciplinary action fulfil requirement repeat willful failure perform duty reasonably assign roche security holding violation law public regulation december december commission crime respectively member cec person gross negligence willful misconduct closely associate hold security show employment table share nonvoting equity security engage conduct bring disgrace disrepute ne ssar restrict stock unit rsus roche andor subsidiary violation roche directive guideline relate business conduct type security value acquire ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salaryremuneration report roche share nonvoting equity security nes december december close relative close relative share ne security holding share ne security holding number number numbertype number number numbertype corporate executive committee schwan r diggelmann hippe ga keller share share oday c wilbur total share share ssar number ssar hold december corporate executive committee schwan r diggelmann hippe g keller oday wilbur total price chf market price ne december chf expiry date grant value ssar chf trinomial model american option v alue accord correspond annual report restrict stock unit rsus number rsus hold december corporate executive committee schwan r diggelmann hippe corporate executive committee g keller replace award correspond psp oday wilbur total grant value rsu chf ne closing price grant date march rsus remuneration component committee remuneration committee corporate executive committee replace discretion vest recipient award correspond psps rsus contain year result nonvoting right receive nonvoting equity security andor equity security remain block share threeyear vest period plus value year vest block period adjustment equivalent sum interest rsu recipient shall align dividend pay vest period company longterm success commitment attributable number nonvoting equity employee company shall increase security individual award grant time rsu awards rsus remuneration component continue allocate individually corporate executive eligible roche employeesstatutory auditor report roche general meeting roche holding ltd basel audit accompany remuneration audit involve perform procedure obtain audit report roche holding ltd year end evidence disclosure remuneration december audit limited report regard compensation loan credit information accord article accordance article ordinance ordinance excessive compensation stock procedure select depend auditor exchange list company ordinance contain judgement include assessment risk section mark grey line include material misstatement remuneration report respective footnote page fraud error audit include remuneration report evaluate reasonableness method apply value component remuneration assess overall presentation remuneration responsibility board director report board director responsible preparation overall fair presentation believe audit evidence obtain remuneration report accordance swiss law sufficient appropriate provide basis ordinance board director opinion responsible designing remuneration system define individual remuneration package opinion opinion remuneration report year auditor responsibility end december roche holding ltd responsibility express opinion complie swiss law article accompany remuneration report conduct ordinance audit accordance swiss auditing standard standard require comply ethical requirement plan perform audit obtain reasonable assurance remuneration report comply swiss law article ordinance kpmg ag ian starkey marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve independent assurance report roche sustainability report corporate governance sustainability committee protection report guideline publish european roche holding ag basel chemical industry council cefic gri standard publish october global reporting initiative engage perform assurance procedure gri provide limited assurance aspect roche group internal corporate reporting manual sustainability report roche hold ag basel sustainability report guidanceeconomic performance consolidate subsidiary roche include annual issue october report report roche materiality determination process corporate level base gri standard publish october scope subject matter global reporting initiative gri limited assurance engagement focus follow define guideline people contribution datum information disclose sustainability report key figure sustainability risk opportunitie roche year end december internally gather collate aggregated management reporting process respect sustainability reporting material aspect inherent limitation preparation safety security health environmental accuracy completeness sustainability indicator protection contribution people key figure subject inherent limitation give nature method relate control environment relation datum determine calculate estimate datum aggregation key figure assurance report read connection materiality determination process roche group level roche internal guideline definition procedure accord requirement gri standard report sustainability performance disclose report design sustainability risk opportunity roche responsibility determination process base roche corporatelevel roche corporate governance sustainability committee activity disclose paragraph risk responsible subject matter criterion management report selection preparation presentation select people key figure disclose page report information accordance criterion responsibility key figure include greenhouse gas emission include design implementation maintenance relate scope scope result business travel internal control relevant reporting process free compress air liquid nitrogen waste generate material misstatement fraud error operation table graph page report responsibility figure roche group level relation political responsibility form independent opinion base contribution disclose page report limited assurance procedure come attention indicate identify sustainability carry work datum report prior information select contain report state reporting period perform work respect material respect accordance report criterion projection target plan perform procedure accordance criterion international standard assurance engagement management reporting process respect isae revise assurance engagement audits sustainability report key figure prepare review historical financial information standard roche base internal policy procedure set require plan perform assurance engagement forth follow obtain limited assurance identify sustainability roche group internal sustainability report guideline information prepare material aspect accordance base responsible care health safety environmental roche internal policy proceduresindependent assurance report roche limited assurance engagement isae revise reviewing principle roche materiality process substantially scope reasonable assurance provide definition development adherence engagement relation risk assessment procedure gris environmental social economic reporting include understand internal control requirement address soundness identification procedure perform response assess risk process determination impact stakeholder peer consequently nature timing extent procedure competition review integration relevant regulatory gathering sufficient appropriate evidence deliberately limit requirement integration key organisational value relative reasonable assurance engagement objective report prioritisation material aspect assurance obtain limited assurance engagement inspect integration sustainability risk reasonable assurance engagement procedure opportunitie group risk management process select depend assurance practitioner judgement adherence internal guideline assessment process datum consolidation independence quality control review management ofand sustainability reporting comply independence ethical process contribution people key figure requirement code ethic professional accountant assess consolidation process datum roche group level issue international ethic standard board accountant found fundamental principle conduct work datum outline integrity objectivity professional competence care subject matter define believe evidence confidentiality professional behaviour obtain sufficient appropriate provide basis assurance conclusion firm apply international standard quality control accordingly maintain comprehensive system quality conclusion control include document policy procedure base work perform describe report compliance ethical requirement professional standard identify roche sustainability report applicable legal regulatory requirement come attention cause believe material respect summary work perform roche group internal sustainability report guideline assurance procedure include base gri standard cefic guideline follow work apply review application roche group guideline roche materiality determination process corporate reviewing application roche group internal level disclose adhere principle guide corporate sustainability contribution guideline factor eg soundness stakeholder determination peer site visit management inquiry review relevance regulatory environment integration visit select site roches pharmaceutical key organisational value objective define diagnostic division germany philippines gri standard south africa switzerland selection base design sustainability risk opportunitie quantitative qualitative criterion determination process corporate level disclose interview personnel responsible internal sustainability function design report data collection site visit internal reporting process collect aggregate roche group level determine understand people datum function design provide application roche internal sustainability guideline appropriate basis disclosure assessment key figure internal reporting process collect aggregate perform test sample basis evidence support contribution datum function design provide select contribution people key figure eg roche appropriate basis disclosure accident rate energy consumption greenhouse gas emission sustainability information mention subject matter relate energy consumption water waste contribution disclose sustainability report roche healthcare institution patient organisation public policy annual report state accordance body philanthropic organisation headcountfte datum reporting criterion train hour concern completeness accuracy adequacy consistency review documentation analysis relevant policy principle zurich february review relevant documentation sample basis include pricewaterhousecooper ag roche group sustainability policy management report structure documentation christophe bourgoin stephan hirschi publish f hoffmannla roche ltd key date group communications basel switzerland tel annual general meeting wwwrochecom march orderdownload publication firstquarter sale internet rochecompublication april email baselwarehouseservicesrochecom fax halfyear result july medium relation tel month sale email rochemediarelationsrochecom october investor relation tel email investorrelationsrocheglobalcom corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement forwardlooke statement earning share growth statement profit forecast interpret annual report contain certain forwardlooke mean roche earning earning share statement forwardlooke statement subsequent period necessarily identify word believe expect match exceed historical publish earning anticipate project intends seek earning share roche estimate future similar expression discussion thing strategy goal trademark legally protect plan intention factor cause actual result differ materially future link thirdparty page provide convenience reflect forwardlooke statement contain express opinion content annual report price thirdparty page expressly disclaim product initiative competitor legislative liability thirdparty information use regulatory development economic condition delay inability obtain regulatory approval bring product market fluctuation roche annual report publish german currency exchange rate general financial market english condition uncertaintie discovery development marketing new product new reporting consist actual annual report use exist product include limitation finance report contain annual negative result clinical trial research project financial statement consolidate financial unexpected effect pipeline market statement regard content management product increase government pricing pressure report article incorporation consist interruption production loss inability aforementione report exception obtain adequate protection intellectual property remuneration report right litigation loss key executive employee adverse publicity print nonchlorine bleach fsccertified paper news coveragedoe patient need nextwe believe urgent deliver medical solution right noweven develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rochef hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom cover show woman diagnose cancer